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ABSTRACT
Prostate Cancer and PSA Testing: Implications of Provider-Patient Communication and SharedDecision Making on National Screening Recommendations
by
Michelle C. Reece
The national recommendations for use of the prostate specific antigen (PSA) test for prostate
cancer screening have been modified over the years as scientific evidence emerged. Current
screening recommendations discourage widespread PSA screening for men at low to average
risk, but provide specific guidelines for shared-decision making between men and their health
providers about the benefits and risks of PSA testing. This study was an examination of
relationships between men‟s assessment of the quality of their care and communication with
their health providers, the extent to which providers engage men in recommended discussions
about PSA testing, and factors associated with shared-decision making and PSA testing.
Secondary data from the U.S. Health Information National Trends Survey 4, Cycle 2 that
included men with no history of prostate cancer and in the recommended age ranges for prostate
cancer screening were analyzed (N=777). Non-Hispanic white men rated their quality of care
higher than men of other races (2 (49, n=635) = 7.23, p = 0.0098), whereas Hispanic men gave
the lowest ratings compared to other men (2 (49, n=635) = 5.42, p = 0.024). Previous PSA
testing was reported by 64% of the men, 56% of whom stated that they discussed screening with
their provider and 80% reported that they were asked if they wanted to have the test done.
However, only 21% - 39% reported having ever discussed the pros and cons of PSA testing.
Discussing PSA testing with a provider was the strongest predictor of obtaining the test
(OR=69.5, CI = 23.6 – 204.6), but the effect was significantly modified when providers and
patients engaged in the shared-decision making process (OR = 47.42, CI = 14.91 – 150.74).
2

Age, education level, and perceived quality of care were consistent positive predictors of PSA
testing. These results indicate there is a gap in provider-patient discussions about PSA screening
and suggest that health providers may not be following the recommended guidelines for the
content of the discussions needed to facilitate shared-decision making. Effective provider-based
interventions to increase shared-decision-making about PSA testing are needed if the national
objectives for prostate cancer screening are to be met.
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CHAPTER 1
INTRODUCTION
Background
The prostate specific antigen test is one of the most important biochemical cancer tumor
markers identified in the 20th century (Kuriyama et al., 1981). The prostate specific antigen
(PSA) is a glycoprotein that is released by both normal and cancerous prostate tissue (Zelefsky,
Eastham, & Sartor, 2011). Landmark achievements in prostate cancer research led to the
detection of elevated levels of the prostate specific antigen in the blood serum of men with
advanced stage prostate cancer and the acceptance of the PSA as a biomarker for prostate cancer
in adult males (Chu, 1994; Balk, Ko, & Bubley, 2003; Stamey & Kabalin, 1989; Stamey et al.,
1989). Also see Appendix A.
Since the mid 1980s the PSA test has been used as a screening tool for prostate cancer for
older adult men and as a test to evaluate and monitor men previously diagnosed with prostate
cancer to measure the effectiveness of their treatment (NCI, 2013d). The PSA test has been
shrouded in controversy since the early stages of research that led to its identification, and this
controversy continues today as many researchers, scientists, and cancer advocates argue about
the use of the PSA as an efficacous screening test for prostate cancer (Barry, 2009; Hayes &
Barry, 2014).
Even though there are other factors that could cause an elevation in a man‟s PSA level,
numerous studies have repeatedly shown that prostate specific antigens are consistently
expressed in nearly all types of prostate cancers. As a man‟s PSA blood level increases so does
his likelihood of having an accurate diagnosis of prostate cancer (Stamey et al., 1989). There
have been very few reported cases where men diagnosed with prostate cancer did not appear to
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have elevated PSA level in their blood serum (Hoffman, 2013; Thompson et al., 2004; Zelefsky
et al., 2011).
Epidemiology of Prostate Cancer in the USA
Prostate cancer screening and particularly the use of the PSA test is an important concern
in public health globally and nationally. Prostate cancer is the most frequently diagnosed
nonskin cancer and the second leading cause of cancer deaths in American men after lung
cancer. Estimates from the National Cancer Institute (NCI) for incidence, mortality, and
prevalence for 2014 indicate that there will be approximately 233,000 new cases of prostate
cancer that account for over 14% of all new cancer cases in 2014 (Siegel et al., 2014). This
figure indicates a decrease in the projected incidence from 2013 where it was estimated that there
would have been approximately 238,590 new cases in 2013 (Siegel et al., 2013). Nearly 30,000
deaths will result from prostate cancer (5% of all cancer deaths). It is further estimated that there
are currently over 2.62 million men living with prostate cancer in the US (NCI, 2013b). The
lifetime risk for developing invasive prostate cancer is 15.3%. In other words nearly one in
seven men will develop prostate cancer in their lifetime (Siegel et al., 2014).
In addition, significant racial disparities exist in prostate cancer incidence and mortality.
African American men are 1.6 times more likely to be diagnosed with prostate cancer and are
more likely to be diagnosed with advanced stage prostate cancer. They are nearly two and a half
times more likely to die from the disease compared to white men and men of other races.
Hispanic men and men of Asian descent are less likely to develop prostate cancer than white men
(American Cancer Society (ACS), 2014).
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Screening Recommendations
There is some disagreement among medical professionals and researchers about the risks,
benefits, and efficacy of prostate cancer screening and whether or not this screening saves lives.
The two existing procedures that are used to screen for prostate cancer are the prostate specific
antigen (PSA) test and the digital rectal exam (DRE). Important questions have been raised
about the accuracy, sensitivity, and specificity of these two tests. The uncertainty is based on
the apparently conflicting results of two large-scale prospective studies. The first study, the
European Randomized Study of Screening for Prostate Cancer (ERSPC) trial, indicated that
PSA screening decreased deaths from prostate cancer by 20% even though there was significant
increased risk for over diagnosis (Schröder et al., 2009). The second study, the U.S. Prostate,
Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, reported that there was no
observed mortality benefit from prostate cancer screening when the PSA Test was combined
with the DRE (Andriole et al., 2009).
Subsequent to the publication of these studies, a number of other systematic reviews and
meta-analyses were carried out to pool together information to provide additional insight into the
controversy (Djulbegovic et al., 2010). A number of national public health organizations that
provide evidence-based guidance and recommendations for disease screening, treatment, and
other medical care have recommended against the widespread use of the PSA test to screen for
prostate cancer. The main argument is that there is insufficient evidence to show that the
potential benefits of PSA testing outweigh the potential harms of screening (Moyer, 2012;
Qaseem, Barry, Denberg, Owens, & Shekelle, 2013; Slatkoff, Gamboa, Zolotor, Mounsey, &
Jones 2011).
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The Centers for Disease Control and Prevention (CDC), the United States Preventive
Services Task Force (USPSTF), the American College of Physicians (ACP), and others
recommend that medical providers should not screen for prostate cancer using the PSA test in
men who are ambivalent (who do not indicate a clear preference) about obtaining prostate cancer
screening, men less than 50 years of age or over 69 years of age or whose life expectancy is less
than 10 to 15 years, and men who are considered to be at low to average-risk of developing
prostate cancer (Moyer, 2012; Qaseem et al., 2013). The American Cancer Society recommends
bi-annual prostate cancer screening for all men ages 50-70 with a life expectancy of at least 10
years, and starting at age 40 or 45 for those considered at high risk (African American men and
men of any race or ethnicity with a family history of prostate cancer), in addition to engaging in
a process of informed or shared decision-making (ACS, 2013a).
The American Urological Society (AUA) recommends no screening for men under 40
years old or over 70 years old, or men who have less than a 10 to 15 year life expectancy. They
recommend screening for men at increased risk from ages 40 to 54 years on an individual basis
and for men 55 years old to 69 years old with shared-decision making and based on the man‟s
preferences and beliefs (Carter et al., 2013). The common recommendation across these groups
is that if men are to be screened using the PSA test it must be done after a detailed discussion
between the patient and his health provider about the basics of prostate cancer, the benefits and
risks of prostate cancer screening, what the results could mean, and what follow-up tests might
be deemed necessary. This discussion should then lead to men making an informed decision or
shared-decision with their health provider about whether they should engage in prostate cancer
screening.
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Even though the common recommendation is that men should be encouraged to engage
in discussions about screening with their health providers so that they can make informed or
shared-decisions, very few studies have looked at whether medical providers are engaging men
in these detailed discussions about prostate cancer and prostate cancer screening. Some studies
suggest that providers may be ordering PSA tests without the shared-decision making process
(Slatkoff et al., 2011; Wilkes et al., 2013).
In addition to the fact that men are much less likely to engage in preventive health
behaviors than women and tend to delay seeking medical care throughout their life course, there
is another major issue that relates to this recommendation (Gast & Peak, 2011; Smith, BraunackMayer, & Wittert, 2006; Wenger, 2011). Research indicates that men are less likely to report
positive engaged relationships and discussions with their health providers, which impacts health
behaviors, medical adherence, and is associated with their overall health outcomes (McCullagh,
2011). Various ideas have been advanced to explain this phenomenon. Some indicate that this is
a result of the way men are socialized to deal with health matters as well as a function of their
attitudes and beliefs about masculinity and the male role (Creighton & Oliffe, 2010; Griffith,
Ober Allen, & Gunter, 2011; Ornelas et al., 2009; Sloan, Gough, & Conner, 2010). Others argue
that poor provider patient relationships may stem from historical issues of trust among some
racial groups (Cheatham, Barksdale, & Rodgers, 2008; Griffith et al., 2011).
Regional differences exist in prostate cancer incidence that may be a consequence of
racial differences and prostate cancer screening up take (Seigel et al., 2014). Other research
suggests that these problems are exacerbated in rural or geographically isolated areas. In many
rural communities health outcomes are poorer and are often a result of the traditional definitions
of masculinity that influences stigma about health care by equating engaging in preventive health
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services and other recommended screenings with male weakness. This stigma is complicated by
the relatively limited research that focuses specifically on men‟s health matters in the USA and
more specifically in the area of rural men‟s health issues (Rural Assistance Center, 2012). The
Appalachia Community Cancer Network (ACCN) reported that burden of cancer among the
people of Appalachia is not getting the attention it deserves (ACCN, 2010; Behringer et al.,
2007). No studies were found that specifically addressed prostate cancer screening rates and
shared-decision making among men and their health providers in Appalachia or compared these
behaviors with non-Appalachian men.
Purpose of the Study
The purpose of this study is to examine the extent to which health providers are engaging
men in discussions about the benefits and risks of PSA testing that facilitate shared-decision
making about prostate cancer screening 2 years since the release of the new screening
recommendations and to identify what factors are associated with shared-decision making and
with obtaining a PSA test. The study therefore addresses the implications of the national
screening recommendations on prostate cancer screening, incidence, treatment, and mortality. A
comparison between Appalachian and non-Appalachian men is included. To accomplish this, a
secondary data analysis of the most current cycle of the Health Information National Trends
Survey (HINTS) that is collected by the National Cancer Institute was conducted.
Significance of the Study
This study is significant for a number of reasons. First, the prevalence of prostate cancer,
the existing disparities, and the controversial recommendations are relevant public health issues.
Second, as part of the evidenced based process, it is also important to evaluate if or how well
health providers have responded to the national guidelines for prostate cancer screening using the
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PSA test. Third, the United States Department of Health and Human Services (HHS) Healthy
People initiative establishes the national agenda for health priorities in the USA. Healthy People
2020 included two objectives that specifically target this issue of prostate cancer and prostate
cancer screening. The two objectives are (1) to reduce the prostate cancer death rate (Objective
C-7) and (2) increase the ratio of men who discuss prostate cancer screening with their health
care provider (Objective C-19) (HHS, 2010; Porsche, 2010). Fourth, it is important to examine
men‟s attitudes towards cancer screening, their perceptions of personal risk, their health seeking
behaviors, as well as the associated factors that significantly impact their health outcomes in this
area. If we could better understand these factors, it may be possible to design more effective
programs to encourage men to talk to their doctors about screening options and to actually obtain
screening if screening were recommended and desired.
This information may help guide the development of community or provider based
interventions to promote shared or informed decision-making for prostate cancer and increase
awareness, education, and screening about this disease. Findings from this study may also
provide insight into how to improve communication between male consumers and their health
providers. It may also help identify health determinants that could lead to a reduction in prostate
cancer disparities. It is known that lower levels of educational achievement and financial
limitations including lack of health insurance were barriers that prevented some men from
getting screened for prostate cancer (Emerson, Reece, Levine, Hull, & Husaini, 2009) but
beyond these socioeconomic factors, other psychological, social, geographic, and cultural factors
are not as well understood. This study will help address these gaps.
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Research Aims
There are four specific aims for this study:
(1) To describe older adult male patients‟ perceptions of the quality of their care and
communication with their health provider and determine whether these perceptions
influence PSA screening behavior;
(2) To examine the extent to which health providers are engaging in a shared-decision
making process by discussing prostate cancer screening according to the most recent
national screening guidelines;
(3) To determine what factors are associated with shared-decision making and providerpatient discussion about PSA testing; and
(4) To estimate the association between male patients‟ perceptions of the quality of their
care, provider patient discussion about prostate cancer, and other factors with PSA
testing.
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CHAPTER 2
LITERATURE REVIEW
The Prostate Gland: Development, Location, and Function
All men are at some risk for developing prostate cancer, yet there are many men who do
not possess correct knowledge about the location and function of this organ that contributes
significantly to male development, health, sexual function, and general quality of life (Winterich
et al., 2009). The prostate gland is a secondary sex, exocrine organ that is an integral part of the
human male reproductive system (Lang, Frame, & Collins, 2009). Prostate development begins
before birth but rapid growth occurs during puberty in preparation for the production of semen.
An enzyme called 5-alpha reductase converts testosterone into a more potent form known as
dihydrotestosterone that signals prostate growth (Hudak, Hernandez, & Thompson, 2006).
Stimulated by these androgens the prostate gland continues to grow until adulthood (Hamilton &
Freedland, 2011). A healthy prostate gland is chestnut shaped and usually the size of a walnut.
The prostate gland secretes a low alkaline fluid that forms approximately 70% of the volume of
the seminal fluid that nourishes and protects sperm during ejaculation (Zelefsky et al., 2011).
The prostate gland is located between the bladder and the penis and is anterior to the
rectum. The urethra passes through the center of the prostate gland. See Figure 1. The prostate
is partly muscular and partly glandular. It is made up of four lobes, four major zones, and ducts
that open in to the prostatic part of the urethra. The anterior lobe, also known as the isthmus of
prostate, is the narrow middle area of the prostate gland that lies anterior to the urethra (in front).
This anterior lobe is mostly nonglandular and is made up of fibromuscular tissue. The median
lobe is a cone-shaped portion of the gland located between the urethra and the two ejaculatory
ducts. The lateral lobes are located to the right and left of the prostatic urethra and form the

21

largest mass of the prostate gland and are continuous toward the posterior lobe. The posterior
lobe is that part of the lateral lobes that the health provider palpates through the rectum during
digital rectal exam (DRE). It lies inferior to the ejaculatory ducts and posterior to the urethra
(NCI, 2012).

Figure 1. Anatomy of the Human Male Genitourinary Tract and Pelvic Area
This image is used with permission by illustrator Terese Winslow © 2010 Terese Winslow; U.S.
Government has certain rights (See Appendix B).
Within the lobes of the prostate there are four zones, the peripheral, transitional, central
zones, and anterior fibromuscular stroma (Zelefsky et al., 2011). The peripheral zone, which is
the largest area, contains about 75% of the glands in the prostate. The peripheral zone is in the
outer most part of the prostate, and the lower peripheral zone is fairly close to the rectal wall.
The majority of prostate adenocarcinomas originate in this area accounting for 70%-80% of all
prostate cancers (Zelefsky et al., 2011). The transition zone surrounds the urethra and is anterior
22

to the central zone. It is mostly made up of smooth muscle and occupies about one third of the
prostate. Approximately 15% of prostate cancers originate in this region. The central zone is in
the center of the prostate and holds most of the remaining glands and surrounds the ejaculatory
ducts. Infrequently cancer would originate in this central zone. However, some research has
shown that carcinomas originating in this zone tend to be more aggressive and have poor
prognoses (Cohen et al., 2008). The anterior fibromuscular zone is nonglandular and consists of
a band of smooth muscle fibers and connective tissue that adjoins the smooth muscle of the
bladder and the external sphincter and that prevents the back flow of semen into the bladder
(Zelefsky et al., 2011).
Pathology of the Prostate
The prostate remains functional and at adult size as long as androgens are present. As
men age they have an increasing chance of developing diseases of the prostate. There are three
main diseases of the prostate: prostatitis, benign prostatic hyperplasia, and prostate cancer.
Prostatitis is inflammation of the prostate gland caused by infection and is most often
characterized by swelling, various urinary problems such as hesitancy, discomfort when passing
urine (dysuria), and increased frequency at night (nocturia). Other symptoms include pain in the
groin, pelvic, or genital area and painful ejaculation, and may sometimes be accompanied by
fever. The peripheral zone of the prostate is the most common site for chronic prostatitis
(Zelefsky et al., 2011).
Benign prostatic hyperplasia (BPH) is a common occurrence in older men and mainly
occurs in the transition zone of the prostate gland. BPH is a nonmalignant enlargement of the
prostate gland. Sometimes the inner section of the prostate that is located around the urethra
continues to grow and can lead to this common condition that is serious prostate problem, but it
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is not cancer. When the prostate gland becomes enlarged, it can easily restrict the flow of urine
due to compression of the urethra leading to some of the same symptoms described above
(dysuria, nocturia, hesitancy, incomplete emptying of the bladder). BPH is a common problem
that affects the quality of life in approximately one third of men older than 50 years and is
histologically noticeable in approximately 90% of all men 80 years and older. As many as 14
million men in the United States have symptoms of BPH (Cunningham & Kadmon, 2013;
McVary et al., 2011; Paolone, 2010). These two prostate conditions are important to note
because often these are problems that get men to the doctor for prostate examinations and
prostate cancer screening because some of the symptoms of these nonmalignant conditions are
similar to those of prostate cancer (Hale, Grogan, & Willott, 2007).
Prostate Cancer Development and Symptoms
Prostate cancer develops as a result of uncontrolled tumor growth in the prostate gland.
Most prostate cancers occur within the peripheral zone of the prostate gland as noted previously,
and it is from this area that most needle biopsies are taken. Prostate cancer develops after an
initial transformation event, followed by mutations of various genes, including the genes for
tumor protein p53 that can lead to tumor progression and metastasis. The enzyme 5-alpha
reductase has been implicated in the development of prostate cancer (Hamilton & Freedland,
2011). Several types of cells are found in the prostate, but approximately 95% all prostate
cancers develop from the gland cells and are therefore termed prostate adenocarcinomas (the
term for cancer that develops in glandular cells). The other 5% of prostate cancers are typically
rare and may include transitional cell carcinomas, small cell carcinomas, and squamous cell
sarcomas (NCI, 2013).
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Grading and Staging of Prostate Cancer
The Gleason grading system was developed by Donald Gleason as a method for
categorizing prostate cancer based on the microscopic appearance of cancer cells (Gleason &
Mellinger, 1974). There have been some adaptations to the staging system, but this has been the
conventional basis for research on the assessment, prognosis, and treatment of prostate cancer
(Epstein, Allsbrook Jr., Amin, Egevad, & ISUP Grading Committee, 2005; Pierorazio, Walsh,
Partin, & Epstein, 2013). The characteristic Gleason scoring illustration in Figure 2 depicts five
tissue patterns that are technically referred to as the grades of the prostate tumor. The Gleason
grade is based upon the degree of loss of the normal glandular tissue architecture (i.e. shape, size,
and differentiation of the glands). The determination of this loss of normal glandular structure
caused by the cancer is represented by a numeric grade, ranging from 1 to 5, where the number 5
represents the worst grade (See Figure 2) (NCI, 2013).
The Gleason score is then calculated based on the two most prevalent histologic grades of
the tumor (grade 1 to grade 5). The primary grade represents the appearance of the majority
tumor and a secondary grade which represents the minority of the tumor. The total Gleason
scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A lower Gleason
score indicates the cancer tissue resembles normal prostatic tissue, whereas a high Gleason score
indicates that the cancer tissue is very different from normal tissue and the tumor is more likely
to metastasize (Epstein, 2011; Epstein et al., 2005). Recent research shows that the differences
in the differentiated grades of a biopsy specimen could provide different prognostic information
so the Gleason score is often reported with its separate components (e.g., Gleason score 3 + 4 =
7; or 4 + 3 = 7) (Amin, Partin, & Epstein, 2011; Helpap, Ringli, Shaikhibrahim, Wernert, &
Kristiansen, 2013; Lavery & Droller, 2012; Pierorazio et al., 2013). Higher Gleason scores are
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associated with increased levels of PSA in the blood serum and several studies have confirmed
that PSA levels were directly proportional to clinically advancing prostate cancer and cancer
volume (Stamey & Kabalin, 1989; Stamey et al., 1989).
1

2

3

4

5

Figure 2. Gleason Grading System Depicting Microscopic Appearance of Cancer cells
Early-stage prostate cancer is localized prostate cancer. This means that the cancer has
not metastasized to local tissues or to other body parts, such as bone, and is still completely
contained within the prostate gland (See Figure 3, Stages I, II, and IIA). Like many cancers, in
the early stages of prostate cancer they are usually no unusual symptoms. When symptoms
develop they may mimic those of BPH that include urinary difficulties and problems achieving
and erection or experiencing painful ejaculation. These issues worsen with increasing stage of
disease (Kurian, Shergill, & Mammen, 2005).
Stage III prostate cancer is called locally advanced cancer. The cancer has spread just
beyond the prostate gland and may be found in the seminal vesicles and/or nearby tissue but not
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reached the bladder, rectum, lymph nodes, or distant organs. When these cancers are locally
invasive, the transitional-zone carcinomas typically first spread to the neck of the bladder, while
the peripheral-zone tumors extend into the seminal vesicles and ejaculatory ducts (Kurian et al.,
2005). Recurrent cancer can occur at this stage, and as the name suggests refers to cancer that
has been previously treated but that has come back in the previously treated area. A return of
prostate cancer is detected by an increase in PSA in the blood after radiation therapy or radical
prostatectomy (NCI, 2013c).
Stage IV or metastatic cancer refers to late stage prostate cancer that occurs when the
cancer cells have spread through the bloodstream or the lymphatic system to other parts of the
body such as the pelvic bone. Prostate cancer has a tendency to metastasize to the bone, in partly
because of the two way interaction between tumor cells and the surrounding bone stroma
(Zelefsky et al., 2011). Numerous studies continue to try to explain the mechanisms for distant
prostate cancer metastasis (Drake et al., 2013; O'Hurley et al., 2013). Advanced stage prostate
cancer often causes additional symptoms such as pain in the regional bones such as pelvis,
vertebrae, and ribs. If prostate cancer metastasizes to the spinal cord, compression can occur that
may cause weakness in the legs as well as fecal and urinary incontinence (O'Hurley et al., 2013).
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Figure 3. A depiction of prostate cancer development through Stages I to IV.
This image is used with permission by illustrator Terese Winslow © 2010 Terese Winslow. U.S.
Government has certain rights (See Appendix B).
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Relationship between PSA Levels and Prostate Cancer Progression
Both normal healthy and neoplastic prostate cells secrete PSA (Vickers et al., 2007) and
an increase in the PSA level can at times be attributed to other benign conditions such as acute
prostatitis, benign prostatic hyperplasia, and other conditions. Even though the level of PSA
expressed on a per cell basis varies, there is no debate on the fact that PSA is consistently
expressed in nearly all prostate carcinomas (Stamey et al., 1989). The absolute value of serum
PSA is useful for determining the extent of prostate cancer and assessing the response to prostate
cancer treatment; its use as a screening method to detect prostate cancer is common but
controversial. In normal healthy males PSA is secreted into prostatic alveoli. It is then pumped
into the prostatic urethra during ejaculation by means of fibromuscular tissue contractions of the
prostate and expelled into seminal fluid. Because PSA is primarily released in prostatic
secretions, only very small amounts of PSA are expected to be found circulating in the blood
serum of a healthy individual. However, in the presence of prostate cancer, the concentration of
PSA in the blood increases significantly (See Figure 4) (Kulasingam, Diamandis, & Vega, 2008).
PSA blood serum levels are generally measured in nanograms per milliliter (ng/mL). The
American Cancer Society reports that the risk of prostate cancer increases as the PSA level
increases, from about 8% with a PSA level of 1 ng/mL to about 25% with a PSA level of 4-10
ng/mL (ACS, 2013). PSA levels that are greater than 10 ng/mL suggest a more than 67%
increased risk of the presence of disease (Ross & Pawlina, 2011). As indicated in Figure 4,
increase in clinical stage leads to an increase in blood PSA levels. Typically healthy men with
no pathological prostate problems display blood serum PSA levels in the range 0.5-2 ng/ml.
These minimal levels of PSA enter the circulation by the process of diffusion through a number
of anatomic barriers. In early development of prostate cancer these PSA levels may increase to
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4-10 ng/ml as a result of destruction of the prostatic tissue. As prostate cancer advances and
becomes invasive, significant amounts of PSA escape into the bloodstream. With advanced
staged cancer these PSA levels may range from 10 ng/ml to 1,000 ng/ml (Kulasingam et al.,
2008).

Figure 4. Prostate cancer invasion and tissue destruction as a measure of PSA elevation.
Reprinted by permission from Macmillan Publishers Ltd: Nature Clinical Practice Oncology
(Kulasingam, Diamandis, & Vega, 2008) See Appendix C.
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The Prostate Specific Antigen (PSA) Test
In 1986 the US Food and Drug Administration (FDA) approved the use of the blood
serum PSA test as a mechanism for tracking the progress of disease and treatment. Eight years
later in 1994, the FDA authorized the PSA test as a screening tool for prostate cancer along with
the use of the standard digital rectal exam (NCI, 2013d). This endorsement of the PSA test led to
a dramatic increase in prostate cancer incidence because of the ability to detect very early stage
prostate cancer in asymptomatic men. However, as alluded to previously, there was and
continues to be concern about the large number of false positive test results and the widespread
attempts to treat prostate cancers that may have not been life threatening that lead to significant
negative side effects and poor quality of life for men (Barry, 2009; Welch & Albertsen, 2009).
Because of the controversy regarding the accuracy and efficacy of the use of the PSA, additional
factors are being studied to attempt to increase the accuracy of PSA testing (NCI, 2013c). These
include:
1.

Age-associated reference ranges – As men age the PSA level will naturally increase
so that a recorded PSA should be compared to the what is considered normal for men
in that age range or age group. However, one important drawback is that most of
these studies have been conducted among predominantly Caucasian men and do not
necessarily account for possible variations based on ethnicity and other factors (NCI,
2013c).

2.

PSA density – PSA levels also increase with increasing prostate size as the benign
cells make PSA. PSA density is the calculated ratio of PSA levels and prostate
volume measured by transrectal ultrasound (TRUS) (Catalona et al., 2000).
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3.

Free PSA to Total PSA ratio – PSA can be measured in two serum types, either total
conjugated (which is bound to other proteins) or free PSA. The percentage of free
PSA tends to increase in benign prostatic hypertrophy compared with prostate
cancer, and increasing size of the prostate correlates with an increase in the
percentage of free PSA. However, a lower percentage of free PSA is associated with
increased prostate cancer risk. Research studies suggest that measuring the
conjugated or free PSA increases the accuracy of diagnosis (El Melegy, Aboulella,
Abul-Fadl, & Mohamed, 2010; Killick, Bancroft, Kote-Jarai, & Eeles, 2012). The
percentage of free PSA relative to the total PSA can be informative as a high ratio is
considered favorable while a low percentage PSA is more commonly associated with
more aggressive prostate cancer (Catalona et al., 2000; Pal, Maitra, Mellon, & Khan,
2013).

4. PSA velocity – This refers to changes in PSA level over time. Sometimes studies
consider PSA doubling time. Although some increase with age is expected, a
substantial change in PSA velocity has been used to predict prostate cancer and to
prompt prostate biopsy. However, some recent research on PSA velocity indicates
that biopsy should not be prompted in the absence of other symptoms (Vickers et al.,
2007).
Each of these factors is important and should be included as part of the discussion and
education that men receive to increase their ability to make an informed decision about getting
screened for prostate cancer using the PSA test. Inadequate or incorrect knowledge about the
PSA test and what the values mean have been shown to influence men‟s decisions about getting
screened (Ukoli et al., 2013).
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The Digital Rectal Exam
The Digital rectal examination (DRE) is one common component of prostate cancer
screening. The DRE is useful to help establish the clinical stage of prostate cancer (Zelefsky et
al., 2011). The DRE is insufficient on its own but helps to provide an estimation of the location,
size, and pathologic stage of the primary cancer. Through the palpation of the prostate via the
rectum this examination can lead to the detection of abnormal prostate conditions such as
induration, asymmetry of the gland, the presence of nodules, and tumors in the posterior and
lateral regions of the prostate gland (Chodak, Keller, & Schoenberg, 1989). Even though the
DRE helps provide prognostic information on prostate cancer and is essential for treatment
planning there are limitations of using the DRE alone to screen for prostate cancer. For example
most Stage I prostate cancers are nonpalpable and may not be felt or discovered using the DRE.
In addition, 15% or more prostate cancers occur in nonperipheral areas and therefore cannot be
detected with a finger examination. Most cancers that are detected by the DRE alone are often in
a clinically or pathologically advanced stage. The greatest value of the DRE is in combination
with the PSA test (Chodak et al., 1989; Hoffman, 2013).
Risk Factors for Prostate Cancer
Age
Even though prostate cancer is very prevalent, other than age, race, and family history
there are very few confirmed risk factors for this disease. Age is, however, the number one risk
factor for developing prostate cancer (ACS, 2014). Figure 5 depicts the proportions of prostate
cancer diagnoses and deaths across the lifespan by age group. Young men are not likely to be
diagnosed with prostate cancer or to die from the disease, but as age increases risk increases
significantly. Nearly 70% of all prostate cancers are diagnosed in men over 55 years of age. It is
estimated that prostate cancer may occur in as many as 80% of all men over 80 years of age.
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Studies show that latent prostate cancers have been found during autopsies performed on older
men who died from other causes even though the number of latent cancers detected at autopsy
declined in the 1990s as a result of the prevalence of screening (Konety, Bird, Deorah, &
Dahmoush, 2005; Zare-Mirzaie Balvayeh Imamhadi & Lotfi, 2012).
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Figure 5. Proportions of prostate cancer incidence and deaths by age group
Race
Race is the next most important risk factor for developing prostate cancer (ACS, 2014).
Incidence and mortality rates of prostate cancer remain significantly higher among AfricanAmerican men as compared to white men. Incidence and mortality rates among Hispanic men
are similar to those of white men, whereas rates of men of Asian origin are lower than in white
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men. Even though there has been a decline in mortality rates among white and AfricanAmerican men, prostate cancer deaths in African American men continue to be more than twice
as high as in white males (Sassani et al., 2011; Siegel et al., 2014). Table 1 below shows the age
adjusted incidence and mortality rates by race or ethnicity for the US based on SEER data (NCI,
2013f).
Table 1.
Age-Adjusted Prostate Cancer Incidence and Mortality Rates by Race or Ethnicity 2006-2010
Race or Ethnicity

Incidence per 100,000

Mortality per 100,000

All Races

152.0

23.0

White

144.9

21.2

White Hispanic

124.9

19.8

White Non-Hispanic

148.2

21.3

Black

228.5

50.9

Asian or Pacific Islander

81.8

10.1

American Indian or Alaska Native

77.8

16.9

Hispanic

125.8

19.2

Many attempts have been made to try to unravel these racial differences in prostate
cancer incidence and mortality. Studies examined differences in tumor grade and stage of disease
at diagnosis (Tewari et al., 2005; Xiao, Tan, & Goovaerts, 2011). African American men and
Hispanic men tend to present with more advanced stages of prostate cancer at initial diagnosis.
African American men also appear to have more aggressive forms of prostate cancer than men of
other racial groups (Kim et al., 2011; Powell, Bock, Ruterbusch, & Sakr, 2010).
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Some studies have examined racial and ethnic differences in male testosterone levels and
the implications for racial differences in the prevalence of clinical prostate cancer (Gann,
Hennekens, Ma, Longcope, & Stampfer, 1996; Makridakis & Reichardt, 2001). Studies have
shown that young African-American men have testosterone levels that are 15% higher than in
their young white counterparts. In addition, there is evidence that 5-alpha reductase appears to
be more active in young African Americans men than in white men, which implies that hormonal
differences may play a role in the differences in prostate cancer development in these two races
(Gill, Wilkens, Pollak, Stanczyk, & Kolonel, 2010). Prostate cancer is an androgen dependent
tumor. Testosterone and dihydrotestosterone are responsible for regulating the epithelial growth
of the prostate and promote metastasis of prostate cancer and it is known that hormones and
growth factors stimulate cell proliferation and have been linked to other cancers. Not only does
androgen administration promote tumor growth in patients with metastatic prostate cancer,
androgen suppression is used in prostate cancer treatment to slow the growth of prostate cancer.
However, studies have not found any consistent association with race and androgen levels in
men with advanced stage prostate cancer (Gill et al., 2010).
Other studies focused on issues related to psycho-social barriers to prostate cancer
screening, health seeking behaviors, as well as differences in access to treatment to try to
explain these disparities (Cheatham et al., 2008; Ferrante, Shaw, & Scott, 2011; Harvey &
Alston, 2011; Mitchell, 2011; Xiao et al., 2011). It is important to note that the independent role
or function of race as a major risk factor for prostate cancer or any other type of cancer is
difficult to separate from the effects of other associated determinants such as education, income,
insurance status, and health-care access (Institute of Medicine, 1999).
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Geographic Disparities in Prostate Cancer Incidence and Mortality
Other disparities in prostate cancer incidence and mortality exist. It is clear that there are
some geographic differences in prostate cancer incidence and mortality (Coleman et al., 2008;
Xiao et al., 2011). Figure 6 depicts the age-adjusted mortality rate for prostate cancer across the
USA for January 1, 2010 (NCI, 2013g). Men living in the southern black belt, the central and
southern Appalachian region, Washington DC, and northwest states have higher prostate cancer
death rates than the rest of the USA. No studies were found that specifically examined prostate
cancer screening in the Appalachian region.

25.91 – 38.77
24.42 – 29.90
23.49 – 24.41
22.48 – 23.48



DC

21.58 – 22.47
15.71 – 21.57
U.S. Rate: 23.05

Figure 6. Age-Adjusted Mortality Rates by State, All Races 2006-2010 per 100,000 (NCI,
2013e)
Appalachia
The Appalachian region of the USA has seen cancer rates that are significantly higher
than the rest of the US population particularly in lung cancer, cervical cancer, and colorectal
cancer (Katz, Pennell, Dignan, & Paskett, 2012; Wingo et al., 2008). A recent epidemiological
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report indicates that cancer is the leading cause of death in the Appalachian region (Blackley,
Behringer, & Zheng, 2012). Appalachia is a 205,000-square-mile region in the USA that follows
the Appalachian range of Mountains from southern New York in the north to northern
Mississippi in the south. Parts of 12 states (New York, Pennsylvania, Maryland, Virginia, Ohio,
Kentucky, Tennessee, North Carolina, South Carolina, Georgia, Alabama, and Mississippi) and
the entire state of West Virginia make up this region. There are 428 counties that are home to
over 25 million residents. Over 40% of the region's population lives in rural areas as compared
to 20% of the national population. Poverty rates in Appalachia are higher than the national
average at 16.1% (NCI, 2013f). Even though significant development and socioeconomic gains
have occurred in the region within recent years, the Appalachian Regional Council (ARC)
reports that there are still nearly 100 counties that are considered economically distressed,
experience significant poverty with limited infrastructure, resources, and very poor health
outcomes (ARC, 2009). These are social determinants that have been shown to impact
preventive health behaviors and help drive health disparities (Wingo et al., 2008).
Within Appalachia there are subregions that are contiguous counties that have relatively
homogeneous characteristics in terms of their demographic profiles, economic status, and
topography (Figure 7). This classification that was developed in the early history of the ARC
and provides a basis for subregional analysis was reclassified in 2009 into smaller areas using
more recent economic and transportation data to provide greater analytical detail for research
purposes (ARC, 2009). Interestingly, cancer incidence also varies to a large extent between
these subregions (Blackley et al., 2012). However, there is very limited published research that
specifically investigates prostate cancer screening behavior, incidence, and death rates within the
Appalachian Region. Wingo and colleagues argue that from a historical perspective, this dearth
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may be a consequence of the unavailability of reliable data across the region. Their study was
among the first to publish cancer incidence rates for a large Appalachian sample. They were
able to identify some differences in incidence rates between Northern, Central, and
Southern Appalachia (Wingo et al., 2008). As these researchers point out, further research is
needed to figure out how these variations within Appalachia may be correlated with access to
care and other socioeconomic factors, or with lifestyle factors or other geographic (urban/rural
residence) factors (Wingo et, al 2008).

Figure 7. Map of Appalachian Subregions (Appalachian Regional Commission, 2009)
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Factors Influencing Prostate Cancer Screening
Several factors have been advanced as barriers and facilitators of prostate cancer screening.
Studies have shown that low literacy and limited prostate health knowledge impede prostate
cancer screening (Blocker et al., 2006; Friedman, Corwin, Dominick, & Rose, 2009; Reynolds,
2008; Ukoli et al., 2013).
One major barrier in a general sense is men‟s attitudes towards health seeking. Research
shows that men are significantly less likely than women to engage in preventive health behaviors
and tend to delay seeking medical care throughout their life course (Gast & Peak, 2011; Smith et
al., 2006; Wenger, 2011). There has also been a proliferation of work that attempts to address
beliefs and attitudes about health and health seeking as well as the gender constructions that
impact the negative health outcomes that men have been experiencing (Blocker et al., 2006;
Broom & Tovey, 2009; Cheatham et al., 2008; Creighton & Oliffe, 2010;). Various ideas have
been advanced to explain this phenomenon. Some indicate that this is a result of the way men are
socialized to deal with health matters as well as a function of their attitudes and beliefs about
masculinity and the male role (Creighton & Oliffe, 2010; Griffith et al., 2011; Ornelas et al.,
2009; Sloan, Gough, & Conner, 2010).
Prostate cancer screening and general health seeking is also complicated by the fact that
men are also less likely to report positive engaged relationships with their health providers
(McCullagh, 2011). Positive provider–patient interactions and relationships have been shown to
positively impact health behaviors and medical adherence and are associated with improved
health outcomes. Griffith and colleagues in their study (2011) indicated that African American
men indicated that they generally did not go to the doctor and that they were typically afraid to
do so. Some men reported that when they actually got to the doctor they were uncomfortable
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with the way the health provider spoke to them or were demanding in their medical
recommendations. Others commented that health providers made recommendations but often
stopped short of informing them on how to engage in critical behavior changes. Issues of limited
trust in doctors were reported in other studies (Cheatham et al., 2008) as well as fear of what a
diagnosis of a serious health condition may mean. The implications of what an elevated PSA
level and the possibility of a diagnosis of prostate cancer means are among the major issues
related to prostate cancer screenings. Fear of the harms associated with screening include impact
on patient quality of life, impact on family, fear about treatment options, and debilitating side
effects of treatment (Friedman et al., 2009; Ukoli et al., 2013). Perceived threats to masculinity
and aversion to the DRE exam have also been advanced as reasons for not obtaining prostate
cancer screening (Ukoli et al., 2013).
These issues relate directly to the quality of care provided in the health seeking
experience. Lee and colleagues reported that issues with inconvenience in accessing heath care
and their perception of difficulty in obtaining quality health care were significant barriers to
prostate cancer screening among minorities. These issues must be addressed as part of the
process to help men decide about screening (Lee, Consedine, Gonzalez, & Spencer, 2012).
In theory, the constructs of the Health Belief Model (HBM) (Figure 8) have often been
advanced in the discussion of health seeking and health screening behavior. This well known
theory (first used to examine why some individuals were reluctant to participate in health
screenings such as for tuberculosis) has been used as a guiding framework for identifying factors
that promote or detract from health seeking is typically a good foundational model for these
types of studies for understanding screening behavior (Glantz, Rimer, & Lewis, 2002). The
HBM is a psychological model that focuses on the attitudes and beliefs of individuals. The
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theory suggests that health seeking is influenced by the individual‟s perception of the level of
threat that is posed by the particular health problem and the value person associates with what it
takes to reduce or eliminate the threat (Becker, 1976; Glantz et al., 2002) that makes it relevant
to the issue of prostate cancer screening.
The HBM explains and predicts health behaviors by exploring constructs such as a
person‟s perceived susceptibility of a disease or illness, the perceived severity of that condition,
perceived benefits of engaging in certain behaviors, perceived barriers to action, cues to action
and self-efficacy. This theory is founded on the idea that an individual will take a health-related
action if he or she perceives that he or she is at risk; feels that an outcome is severe enough to
warrant action; has a confident expectation that by taking a particular action the negative health
condition can be avoided; and believes that he or she has the ability and/or resources to
successfully take action (Glanz et al., 2002; Hayden, 2014).

Individual
Perceptions

Perceived
Susceptibility &/or
Perceived Severity

Modifying Factors

Likelihood of
Action

Age, Sex,
Ethnicity,
Socioeconomic
status, Knowledge

Perceived Benefits
minus Perceived
Barriers

Perceived Threat

Likelihood of
Behavior

Cues to Action

Figure 8. The Health Belief Model (Hayden, 2014).
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The constructs of the HBM have also been used to examine prostate cancer screening
behavior and was shown to useful in assessing men‟s perception of their prostate cancer risk, the
severity of the disease, what would motivate them to get screened, as well as their perception of
benefits and barriers to screening (Çapık & Gözüm, 2011, Odedina et al., 2011). The strongest
cues to action or reasons for obtaining prostate cancer screening even prior to the new guidelines
by the USPSTF was a recommendation or an order for the exam by a physician, personal
knowledge and perceived risk for getting prostate cancer (Emerson, et al., 2009; Ferrante et al.,
2011; Finney Rutten et al., 2005; Odedina et al., 2011). The perceived quality of care and
interactions with the doctor, whether the patients are being provided with accurate and balanced
information on prostate health, the benefits and harms of screening, individual patient‟s risk, in
the context of their personal values and other modifying factors of prostate cancer risk is the
focus of this study. In other words are health providers following the recommendations for
prostate cancer screening given by the USPSTF.
Provider-Patient Communication
Communication is commonly defined as the exchange of information from one source to
another. The effectiveness of communication is impacted by the content of the information, the
relationship or dynamics between the source and recipient, and the methods used to convey the
information (Corcoran, 2007). Health communication is the transactional discussion between the
health provider or health educator and the patient in relation to some form of health promotion,
the prevention of illness and disease, and medical decision making (Corcoran, 2007).
Communication and interpersonal relationships and are among the core clinical competencies
required of physicians (Duffy et al., 2004). In the medical setting the health provider‟s
communication skills not only include the ability to conduct a clinical interview to obtain the
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information needed for an accurate diagnosis or to provide therapeutic information but also their
ability to form a trusted, caring relationship with the patient. Effective communication can help
patients make informed decisions, cope with possible medical diagnoses, and better manage their
health whereas ineffectual communication contributes to breakdown in care and undermines the
overall doctor-patient relationship (Ha & Longnecker, 2010).
Factors Influencing Provider-Patient Communication
Several individual patient factors impact the quality of communication between the
patient and the health provider. Epstein and colleagues (2005) identified four major categories
of factors influencing the quality of the communication between health providers and their
patients. These are patient factors, provider factors, relationship factors, and health clinic factors.
Patient factors include the individual‟s personality, self-efficacy, culture, values, family
background, socioeconomic status, previous illness and medical care experiences, attitudes
toward health providers, and perception of severity of the current illness (Epstein et al., 2005).
Characteristics of the health provider also play a critical role. These may include
personality, supportiveness of the patient‟s autonomy, cultural competence, risk aversion, the
presence or absence of a patient-centered orientation, and knowledge of the patient as a person.
This knowledge is often developed over time and can be impacted by the length of the
relationship or number of times the patient has seen the particular provider or attended the
healthcare facility. Stronger relationships are built when patients experience trust, when
expectations of care are met, and when there is concordance or understanding of values and
beliefs (Epstein et al., 2005).
Clinic factors or issues with the health system can also impact the provider-patient
interaction. In addition to the general issues of health care access and medical insurance, the
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quality of communication between patient and provider is affected by satisfaction or frustration
with wait times, ease of obtaining appointments, and length of time in the clinical encounter with
the doctor and the physical environment of the office, clinic, or health center (Epstein et al.,
2005).
Impact of the Quality of Patient Physician Communication
In general, the quality of patient provider communication critically impacts health
seeking behavior and overall health outcomes. It has been shown that patients who experience
better interactions with their providers tend to be more informed patients, are more actively
involved in their medical care, make better health decisions, have a shared understanding of the
circumstances of their health with their physicians, and are often more adherent to their medical
treatment (Epstein, Alper, & Quill, 2004). On the other hand barriers and break downs in
communication have been shown to lead to patient dissatisfaction, complaints of lack of caring,
and concern about their problems on the provider‟s part that as some researchers point out also
contribute to increased likelihood of medical malpractice law suits (Ha & Longnecker,
2010; Levinson, Lesser, & Epstein, 2010). These factors also contribute to racial disparities in
the health care experience of different groups (Saha, Arbelaez, & Cooper, 2003).
Other studies have found that health providers tend to communicate differently with
patients based on their demographic differences such as age, race, level of education, and income
(Siminoff, Graham, & Gordon, 2006). It is important that providers understand the importance
of racial, cultural, and socioeconomic diversity among their consumers and may need to tailor
their attempts to educate and inform their patients. Inappropriate differences in communication
may lead to disparities in patient health outcomes. Minority patients report experiencing poorer
communication between them and their health providers. Unquestionably, quality patientcentered communication is associated with increased trust of health providers that is associated
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with medical adherence and continuity of care (Cooper et al., 2003; Zolnierek & Dimatteo,
2009). Successful doctor-patient communication is crucial to developing an effective therapeutic
doctor-patient relationship and is critical to the delivery of the optimal health care.
Epstein and Street (2007) devised a model (as seen in Figure 9) to show the relationships
between patient-centered communication and health outcomes. The model includes six basic
functions of provider-patient communication (1) foster healing relationships; (2) exchange
information; (3) respond to patients‟ emotions; (4) manage uncertainty; (5) make informed
decisions; and (6) enable patient self-management. One of the goals is to assess patients‟ selfrating of the quality of this type of communication with their providers in their most recent
encounters. These key constructs are the basis for a number of questions in the HINTS Survey.
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Figure 9: Patient-centered communication and health outcomes in cancer care (Epstein & Street,
2007). Source: Epstein, & Street, Jr. (2007) Patient-centered communication in cancer care:
Promoting healing and reducing suffering. Bethesda, MD: National Cancer Institute.
Shared-Decision Making and PSA Testing
Shared-decision making is a process that allows patients and their providers to work in
partnership to make health care decisions that not only considers the best scientific evidence and
methods available for medical care but also considers the patient‟s beliefs, values, concerns, and
personal preferences (Elwyn et al., 2012). Shared-decision making honors the patients‟ rights to
be fully informed of all possible options and potential harms and benefits of each option so that
they can maintain their sense of personal autonomy. The potential outcomes must be discussed
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so that patients can fully grasp the implications of their decisions regarding their course of action
(Charles, Gafni, & Whelan, 1997; Politi & Street, 2011). In this process the health provider‟s
knowledge and expertise is balanced with providing support to the patients to help them make
the best possible decisions about their health care (Elwyn et al., 2012).
In order to achieve this, relationships between health providers and patients must be built
and nurtured through positive clinical encounters. When information is shared, patients should
be encouraged to carefully consider and reflect on the impact that the information could have on
their health, general wellbeing, and lifestyle and be able to express their views, seek additional
opinions and consult with family members or significant others throughout the decision-making
process (Elwyn et al., 2012). Shared-decision making is especially important when it comes to
sensitive conditions and screening methods such as prostate cancer screening using the PSA test
and the digital rectal exam. Research has shown that patients often experienced pressure in their
decisional guidance. This is influenced by the health provider‟s preferences or possible biases
toward certain option, their communication styles and approaches, as well as patients‟ own ideas
about the level of personal concern exhibited by the providers (Thorne, Oliffe, & Stajduhar,
2013). However, most often patients participate in decisions about medical procedures and
treatments without a complete understanding of their options and without appropriate decisional
support materials (Fowler Jr., Levin, & Sepucha, 2011; Hoffman et al., 2009).
Epstein et al. (2004) describe the following important steps for effective sharing of
clinical evidence with patients facing medical decisions. These include (1) building the
partnership; (2) understanding the patient‟s expectations and experience; (3) appropriate framing
and communicating the clinical evidence; (4) having a balanced discussion on the uncertainties,

48

risks and benefits; (5) providing recommendations and obtaining feedback ; and (6) double
checking with the patient for understanding and agreement.
With the ongoing debate about the use of the PSA test much of the emphasis on prostate
cancer screening is now centered on informed and shared-decision making. In this process men
who meet the criteria for screening should be educated about prostate cancer, the harms, benefits,
limitations of screening, and what the results of a PSA test could mean for their health before
they are offered or asked if they want to be screened (ACS, 2013; AUA, 2013; Ukoli et al.,
2013). Given the uncertainty around the use of the PSA test, careful discussions are necessary to
ensure that patients do not experience lower levels of satisfaction in the decision making process
(Politi, Clark, Ombao, Dizon, & Elwyn, 2011). Research shows that shared-decision making is
even more critical when there is inadequate clinical evidence or there is ambivalence about
medical procedure (Epstein & Gramling, 2013; Politi, Lewis, & Frosch, 2013; Politi & Street,
2011).
Based on the USPSTF recommendations for shared-decision making, a number of issues
must be discussed. Consequently to determine if shared-decision making is happening in the
clinical setting shared-decision making must be seen not as a clear-cut, dichotomous variable,
but should be considered a continuous measurement of the various components suggested by the
USPSTF (Sheridan, Harris, & Woolf, 2004; Woolf & Krist, 2009).
Conceptual Framework
Based on the preceding discussion on the Health Belief Model, the theory behind patient
centered communication and shared-decision making a mixed model was devised for this
proposal (See Figure 10 below). This model incorporates constructs from the various approaches
as they influence shared-decision making about PSA testing and actual PSA testing. What the
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model presupposes is that social determinants impact patient factors that, along with certain
health provider factors, impact patient perceptions of provider patient communication that then is
associated with, determines or predicts whether shared-decision making occurs. The model
shows how these factors impact current screening guidelines objectives and the national
objectives for prostate cancer outcomes in America. In other words if shared-decision making is
occurring then we can determine if national recommendations are being followed by health care
providers and if the Healthy People 2020 C-19 objective is being met.
Individual Determinants
 Demographics
 Personal History
 Attitudes
 Beliefs
 Health Behaviors

 Perceptions of
Quality of care
 Perceptions of
Quality of Providerpatient
communication

Health Provider Factors
 Patient –centered
orientation
 Communication Skills
 Recommend
Screening/Order test

Social Determinants
 Health Access
 Health Utilization
 Other factors

Shared-Decision
making about PSA
Testing

PSA Testing

Common National
Screening Guidelines
Recommendations
Achieved

Healthy People 2020
Objective C-19
Addressed

Arrow Key
Influencing Factors
Associations to be Tested
Indirect Outcomes
Figure 10: Conceptual Model of Factors impacting Shared-decision Making and PSA Testing
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CHAPTER 3
METHODS
The aims of this study were to: (1) describe older adult male patients‟ perceptions of the
quality of their care and communication with their health provider and determine whether these
perceptions influence PSA screening behavior; (2) examine the extent to which health providers
are engaging in a shared-decision-making process by discussing prostate cancer screening
according to the most recent national screening guidelines; (3) determine what factors are
associated with shared-decision making and provider-patient discussion about PSA testing; and
(4) estimate the association between male patients‟ perceptions of the quality of their care,
provider patient discussion about prostate cancer, and other factors with PSA testing. The
variables were also examined to identify whether there were regional or racial differences in any
of these factors.
Study Design
This study used secondary, publicly available data from the U.S. Health Information
National Trends Survey 4 (HINTS 4) Cycle 2, 2013. HINTS 4 is a cross-sectional survey of a
nationally-representative sample of adults living in America. The survey is conducted every 2
years and is used to assess the general impact of the health information environment on adult
health behaviors. HINTS 4 measures how the public accesses and uses health information. It
assesses the extent to which people participate in preventive health and other promoting
behaviors. It examines how information technology is used to manage health and health
information. The HINTS 4 survey also includes several measures that specifically focus on
cancer prevention and control (NCI, 2013b).
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Data Collection
Data collection for HINTS 4 Cycle 2 began on October 9th, 2012, and was completed on
January 11th, 2013. The Cycle 2 survey was conducted exclusively by mail. A minimal $2
monetary incentive was provided to potential respondents to encourage participation. The survey
was self-administered and respondents returned their survey via a preaddressed envelope
included in the survey packet. The sampling strategy for the HINTS Cycle 2 survey comprised a
two-stage or two-step design. First a stratified random sample of household addresses was
selected using available lists of US residential addresses, and then at the second-stage, a sample
of adults 18 years and older within the sampled households was obtained (NCI, 2013b).
The household addresses included in the sampling frame were provided by the Marketing
Systems Group (MSG). Addresses were divided into three groups or strata. The first stratum
included addresses in high minority population areas. The second stratum included addresses in
areas with low minority population areas. The third stratum included addresses located in
counties located in the Central Appalachia region regardless of minority population or
concentrations. All occupied residential addresses in the United States that were present in the
MSG household database, including seasonal addresses, post office boxes, and redirected mail
addresses were eligible for inclusion in the sampling frame. The questionnaire was first mailed.
If there was no response a follow-up post card was sent as a reminder. Up to two more
questionnaires were mailed to nonresponders. Households that were identified as potential
Spanish speaking households received both English and Spanish versions of the survey. More
extensive information regarding the sampling procedures are detailed in the HINTS 4 Cycle 2
Methodology Report (NCI, 2013b).
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Sample Selection
There were 3,630 respondents included in the total HINTS 4 Cycle 2 sample. Sample
weights were calculated to estimate a national sample using the HINTS 4 Cycle methodology for
sample weights described in the HINTS 4 Cycle 2 Methodology Report (NCI, 2013b). This data
analysis featured only men in the recommended age brackets for prostate cancer screening based
on the American Cancer Society‟s recommendations (N = 777). This included all African
American men 40 to 75 years old who are considered at an increased risk for prostate cancer.
Men from other racial groups between ages 50 and 75 years were included in the sample (Smith,
Brooks, Cokkinides, Salsow, & Brawley, 2013). This study does not account for men with an
increased risk for prostate cancer because of the familial risk of having a first degree male
relative with a history of prostate cancer. While this HINTS data set asks a general question
about having a family history of cancer, it does not specifically query what type of cancer and
the degree of relationship.
Research Questions and Survey Items
The aims of this study were addressed by the following four research questions: (1) how
do older adult male patients rate their perceptions of the quality of their care and communication
with their health provider? (2) To what extent are health providers engaging in the shareddecision-making process by discussing prostate cancer screening according to the most recent
national screening guidelines? (3) What factors are associated with level of shared-decision
making and provider patient discussion about prostate cancer screening? (4) What is the
relationship of male patient‟s perceptions of the quality of their care, shared-decision making,
and other putative factors on PSA testing?
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Demographic items included in the analysis included age, race or ethnicity, marital status,
level of education, household income, employment status, and residence in the Appalachian
region. These personal characteristics that have been shown to impact health awareness, beliefs,
attitudes, health seeking behaviors, and other health interactions were first used to describe the
sample and also served as covariates in multivariate analyses and to adjust for possible
confounding.
Perceptions of Quality of Care and General Provider-Patient Communication
Research Question 1: How do older adult male patients rate their perceptions of the quality of
their care and communication with their health provider?
To address this question respondents were asked to assess the quality of the interaction
they had with their health providers (doctors, nurses, or other health professionals) in the 12
months prior to completing the survey. These questions were not specific to prostate cancer
screening but were a broad assessment of the general quality of their provider-patient
communication. Respondents were asked how often did their health provider:
(a) Give them the chance to ask all the health-related questions they had;
(b) Give them the attention they needed regarding their feelings and emotions;
(c) Involve them in decisions about their health care as much as they wanted;
(d) Make sure they understood the things they needed to do to take care of their health;
(e) Explain things in a way they could understand;
(f) Spend enough time with them; and
(g) Help them deal with feelings of uncertainty about their health or health care?
The answer choices ranged from 1 = always; 2 = usually; 3 = sometimes; 4 = never. These
scores were reverse coded and then summed to create a continuous variable of level of
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satisfaction with provider patient communication with a minimum score of 7 and maximum
score of 28. Higher scores represent higher perception of the level of provider engagement and
interaction. The mean of these seven items was used as a measure of the quality of the
communication that is similar to the method used in previous research (Rutten, Auguston, &
Wanke, 2006; Underhill & Kiviniemi, 2012). Cronbach‟s alpha reliability for this created scale
was  = 0.93, which indicates very high internal consistency in this sample. Five items in this
measure are adaptations of five similar items developed for the Consumer Assessment of Health
Providers and Systems (CAHPS, previously called Consumer Assessment of Health Plans). The
responses to these items were categorized as either “always” or “not always” (usually,
sometimes, never). For most of these items between 43% and 67% of the participants responded
„always‟. These responses were dichotomized to „always‟ or „not always‟ to be used in the
regression analyses addressing research questions 3 and 4. This method has been used in
previous research studies using previous HINTS data sets (DeVoe, Wallace, & Fryer, 2009;
Wallace, Chisolm, Abdel-Rasoul, & DeVoe, 2013).
Respondents were also asked to rate the quality of the care they received from their
providers in the last 12 months. Responses ranged from 1 to 5 (where 1 = excellent and 5 =
poor). This scale was also reverse coded to reflect that higher scores indicate greater satisfaction
with quality of care in the respondents‟ most recent health encounters. These two ratings were
subsequently used as predictors of shared-decision making and PSA testing.
For research question 1, bivariate analyses including cross tabulations with chi squares
(2) estimated associations between (a) perceptions of quality of care and (b) level of interaction
with their health provider questions and demographic variables (age group, marital status,
education level, etc), residence in Appalachia, and ever having a PSA test.
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Provider Communication about Prostate Cancer and PSA Testing
Research Question 2: To what extent are health providers engaging in shared-decision making
process by discussing prostate cancer screening according to the most recent (2011) screening
guidelines?
Informed and shared-decision making are key issues that relate to PSA screening and
form the common recommendations among the various agencies with opinions on the use of the
PSA test. Seven questions were used to assess respondents‟ experience of an informed
discussion regarding the use of the PSA test with their health provider. These seven questions
(Q1 to Q7) are:
Q1.

Have you ever had a PSA test” (1 = Yes; 2 = No)? All male respondents were
also asked to respond to the following questions that examine conversations they
may have had with their doctors or other health care providers regarding the PSA
test:

Q2.

Has a doctor ever discussed with you whether or not you should have the PSA
test (1 = Yes; 2 = No)? If participants responded yes to this question, they moved
to the next question, otherwise they skipped to the next three questions.

Q3.

Did the doctor ask you whether or not you wanted to have the PSA test (1 = Yes;
2 = No)?

Q4.

Did a doctor ever tell you that some experts disagree about whether men should
have PSA tests (1 = Yes; 2 = No)?

Q5.

Has a doctor or other health care professional ever told you that the PSA test is
not always accurate (1 = Yes; 2 = No)?
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Q6.

Has a doctor or other health care professional ever told you that some types of
prostate cancer are slow growing and need no treatment (1 = Yes; 2 = No)?

Q7.

Has a doctor or other health care professional ever told you that treating any type
of prostate cancer can lead to serious side effects, such as problems with
urination or having sex (1 = Yes; 2 = No) (NCI, 2013a)?

Questions 4 through 7 (Q4 to Q7) were used to create a summated scale for measuring
shared-decision making of PSA testing. Each question was recoded so that all „No‟ responses
were given a score of zero. Yes responses to the questions were scored one. (0=No; 1=Yes).
Summated scores ranged from 0 to 4. Higher scores represent increased shared-decision making
with patient about PSA testing. The Cronbach‟s alpha reliability score was calculated for the
shared-decision making variable ( = 0.78). This continuous variable was used as the measure
for shared-decision making in the multivariate models in research questions 3 and 4. This
method is suggested by previous research examining shared decision making for PSA testing
(Woolf & Krist, 2009).
Means and standard errors were reported. Bivariate analyses including cross tabulations
with chi squares (2), and univariate regressions estimated associations between age, race or
ethnicity, marital status, level of education, employment status, household income, health
insurance status, general health rating, history of cancer, and informed decision making about
prostate cancer screening with history of PSA screening.
Predictors of Shared-Decision Making
Research Question 3. What factors are associated with level of shared-decision making and
provider patient discussion about prostate cancer screening?
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Several variables including demographic and other independent variables were examined
in relation to this continuous dependent variable, shared-decision making. The demographic
items that included in these analyses are age, marital status, education, work status, household
income, and health insurance status. These personal characteristics that have been shown to
impact health awareness, beliefs, attitudes, health seeking behaviors, and other health
interactions were also used to describe the sample but were also included as covariates in
multivariate analyses and to adjust for possible confounding.
Other covariates include general health status and number of chronic medical conditions.
General health status was measured using a standard five-point scale where responses ranged
from 5 = poor to 1 = excellent (Ware, Kosinski, & Keller, 1996). The number of major chronic
conditions were calculated based on participants‟ responses to the question of whether they were
ever told by a doctor or other health professional that they had any of the following medical
conditions: diabetes, high blood pressure, any heart condition such as heart attack, angina, or
congestive heart failure; chronic lung disease, asthma, emphysema, or chronic bronchitis;
arthritis or rheumatism; and depression or anxiety disorder (1= Yes; 2=No) (NCI, 2013a). The
number of chronic medical conditions a person has is associated with number of physician visits
(Ashman & Beresovsky, 2009) and increased likelihood of PSA testing (Halpern et al., 2013). A
continuous variable for the sum of the number of chronic conditions was created and included to
adjust for possible impact PSA testing.
The measurement of health care use included four variables: having a regular doctor or
medical home; health insurance; estimate of time since their last nonemergency medical visit;
and the total number of medical visits within past year. Each of these questions was used
previously on other national validated surveys such as the Behavioral Risk Factor Survey
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(BRFSS) (CDC, 2011). Respondents were first asked if they had a usual source of health care.
The question queried if they had a particular doctor, nurse, or other health professional who they
saw most often not including psychiatrists and other mental health professionals (1=Yes, 2=No).
The subsequent question asked the respondents if they had any kind of healthcare coverage,
including health insurance, prepaid plans such as HMOs, or government plans such as Medicare
(1=Yes, 2=No).
A third question asked respondents to provide an estimate of time since their last visit to a
doctor for a routine checkup or general physical exam that was not because of a specific injury,
illness, or condition. Responses ranged from: 1 = Within past year (anytime less than 12 months
ago); 2 = Within past 2 years (1 year but less than 2 years ago); 3 = Within past 5 years (2 years
but less than 5 years ago); 4 = 5 or more years ago; 5 = don‟t know; and 6 = never (NCI, 2013a).
The fourth question asked respondents to report how many times they sought medical
care from a doctor, nurse, or other health professional for themselves, excluding emergency
room visits. Responses ranged from: 0 = none; 1 = 1 time; 2 = 2 times; 3 = 3 times; 4 = 4 times;
5 = 5 to 9 times; and 6 = 10 or more times (NCI, 2013a). This variable was used as a continuous
measure to examine relationships between number of medical visits, levels of satisfaction with
provider-patient communication, shared-decision making, and screening behavior.
Perception of disease risk has been shown to impact preventive health behaviors (Becker,
1976) and screening for cancer. Respondents were asked to report their perceived likelihood of
getting cancer in their lifetime. Likert scale responses for the variable measuring cancer risk
perception ranged from 1 = Very unlikely to 5 = Very likely. They also rated their likelihood of
getting cancer in comparison to other people their age. These responses ranged from 1 = much
less likely to 5 = much more likely. A third question asked respondents to select the option that
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best reflected their opinion on the statement "I feel like I could easily get cancer in my lifetime."
Options for this were (1) I feel very strongly that this will NOT happen; (2) I feel somewhat
strongly that this will NOT happen; (3) I feel I am just as likely to get cancer as I am to not get
cancer; (4) I feel somewhat strongly that this WILL happen; and (5) I feel very strongly that this
WILL happen. Participants were also asked if any family members ever had cancer (1 = Yes; 2
= No; 4 = Not sure). A history of cancer in family members may influence a person‟s perceived
risk. Respondents were also asked how much they agreed or disagreed with the statement: "I'd
rather not know my chance of getting cancer." 1 = strongly agree, to 4 = strongly disagree. A
multivariate linear regression analysis tested the independent associations between the putative
independent variables and shared-decision making while adjusting for age, race, marital status,
insurance status, and other potential confounders.
Predictors of PSA Testing
Research Question 4. What is the relationship between male patient‟s perceptions of the quality
of their care, provider patient discussion about prostate cancer, and PSA testing?
Four multivariate logistic regression models were used to estimate the strength of the
associations of various predictor variables on PSA testing. The various independent predictors
have been described above. In Model 1 the various demographic variables were regressed on the
PSA testing variable along with the variables assessing quality of care, perceived cancer risk,
feelings about wanting to find out about a cancer diagnosis, number of chronic medical
problems, and having had a recent medical visit. This model is the basis for comparison for
subsequent models. Model 2 includes all variables from model 1 and adds the shared-decision
making variable. Model 3 includes model 1 variables and the variable assessing if the doctor had
ever discussed PSA testing. In Model 4 each of the variables of interest was regressed on PSA
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testing. A test for an interaction effect was conducted between shared-decision making and the
variable that addressed the question of whether the doctor discussed PSA testing.
Statistical Analysis
All data were analyzed using SAS 9.2 statistical software (SAS Institute; North Carolina).
Sample weights were used in the survey analysis to assign an increased relative value to some
members of the sample as compared to others. Weights are necessary when the sample is
selected by unequal probability sampling. They are also used in poststratification and to adjust
for nonresponse (Kalton, 1983). Sample weights were applied to all analyses in order for more
accurate inferential statistics to be calculated and to estimate the values for a national sample.
This is one of the analytic recommendations given by the National Cancer Institute for the
HINTS data because of biases introduced through planned over-sampling and differential
response rates. The specific analytic method used was the jackknife procedure with 50 replicate
weights (NCI, 2013a). This procedure provides a method of reducing bias and obtaining
standard errors in situations where the standard methods might underestimate errors and lead to
type-1 errors (Severiano, Carriço, Robinson, Ramirez, & Pinto, 2011).
Descriptive analyses summarized the general characteristics of the sample and their
encounters with their health providers. These included frequencies, means, and standard errors.
Standard errors were reported instead of standard deviations because while standard deviations
are most frequently used as a measure of the dispersion of a characteristic in a sample, the
standard error is used as an inferential statistic to estimate a population characteristic (Biau,
2011). These univariate and bivariate analyses were calculated for each variable of interest to
provide descriptive data for the sample. Unadjusted univariate logistic regression models were
used to clarify any within group differences.
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Multivariate regression analyses estimated the effects of the independent variables (health
care visits, number of chronic medical conditions, having a regular provider, perceived quality of
care and provider patient communication, perceived cancer risk, and no desire to know if cancer
is present) on shared-decision making (linear regression), and PSA screening (logistic
regression). These regression models adjusted for sociodemographic factors such as age, race,
marital status, education, income, insurance status, and other covariates described above. The
descriptive summary of the sample and the findings from the multivariate analyses are reported
in the following chapter. Where appropriate, analyses are represented in tables and graphs.
Human Subjects Protections
This study is a secondary data analysis of data collected by the National Institutes of
Health. It does not contain any identifiable health information and is publicly available.
Appendix E contains the HINTS data use agreement obtained for this study. The East Tennessee
State University Institutional Review Board (IRB) determined that this research study met the
criteria for being exempt from IRB review because it did not meet the conditions that would
represent human subject‟s research. See Appendix F.
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CHAPTER 4
RESULTS
Secondary data from the U.S. Health Information National Trends Survey 4 (HINTS 4
Cycle 2) were used for this study. The sample consisted of 777 men who met the criteria for
inclusion based on the American Cancer Society‟s recommendations for PSA screening (Smith
et al., 2013). African American men between the ages 40 to 75 years and all other ages 50 and
75 years were included in the sample. This study did not account for men with an increased risk
for prostate cancer due to a familial risk of having a first degree male relative with a history of
prostate cancer because this information was not included in the HINTS 4 Cycle 2 dataset. Men
with a previous history of prostate cancer were excluded from the sample. The data were
weighted to estimate the results to the national population represented by this sample (NCI,
2013a).
Descriptive Characteristics of the Sample
Descriptive analyses were conducted to measure the frequencies and distribution of
demographic characteristics and the variables of interest for the men in the sample. The
weighted average age for the men was 59.42 years (SE = 0.20; CI 59.02 – 59.81). About 4% of
the black men fell in that lowest age category (40-49 years) for recommended screening based on
increased risk for prostate cancer. Approximately two thirds of men were non-Hispanic white
men (67%), nearly 12% were non-Hispanic black men, 9 % were Hispanic, and the other 12%
did not identify their race. About 70% reported being married or living as married.
Approximately 63% of the men had more than a high school education. Just over half the men
reported being currently employed. Half of the men reported having an annual household
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income that was $50,000.00 or higher. More specific details of these descriptive statistics are
presented in Table 2 below.
Table 2.
Sample Characteristics with Weighted Percentages for Total Sample by History of PSA Testing
Variables

Total Sample

Ever Had PSA

Never Had PSA

N=777

n=503

n=258

Subcategories
n

Weighted %

n

Weighted%

N

Weighted%

40-49 years

27

4.28

7

33.88

20

66.12

50-59 years

316

49.10

166

52.71

142

47.29

60-69 years

320

34.37

244

76.98

72

23.02

70-75 years

114

12.27

86

84.91

24

15.08

Hispanic

85

8.97

51

63.76

32

36.24

Non-Hispanic White

480

67.66

330

67.80

141

32.20

Non-Hispanic Black

109

11.38

61

54.59

46

45.41

Other Race or Not

103

11.98

61

53.56

39

46.44

Married or Cohabiting

473

70.93

342

71.52

123

28.47

Single never married

107

12.10

104

53.28

78

46.72

Separated/Divorced/Widowed 188

16.24

51

35.47

54

64.52

Not Ascertained

0.72

6

76.50

3

23.50

Age Categories**

Ethnicity

Ascertained
Marital Status**

9

Within Group Differences based on Chi Square Analyses: ** p < .01; ** p < .001
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Table 2. (Continued )
Variables

Total Sample

Ever Had PSA

Never Had PSA

N=777

n=503

n=258

Subcategories
n

Weighted %

n

Weighted %

n

Weighted %

Less than High School

80

15.15

41

63.18

36

36.82

High School Graduate

167

21.17

83

47.67

77

52.33

Some College

233

34.37

154

65.77

76

34.23

Bachelor‟s Degree

177

17.55

128

69.53

48

30.47

Graduate Degree or Higher

117

11.31

96

82.59

19

17.41

3

0.45

1

76.86

2

23.14

Employed

367

51.72

225

59.25

133

40.75

Unemployed

57

6.16

23

42.27

31

57.73

Retired

265

28.38

208

80.44

54

19.56

Disabled

66

11.35

35

55.22

30

44.78

Other or Not Ascertained

20

2.19

12

73.63

10

26.37

Less than $20,000

145

15.97

61

39.62

79

60.38

$20,000 to < $35,000

97

12.69

62

67.85

33

32.15

$35,000 to < $50,000

90

11.20

53

59.83

34

40.17

$50,000 to < $75,000

120

16.49

88

68.33

28

31.67

$75,000 or more

236

33.94

179

72.71

55

27.29

Not Ascertained

89

9.69

60

67.27

29

32.73

Education**

Not Ascertained
Work Status**

Household Income**

Within Group Differences based on Chi Square Analyses: ** p < .01; ** p < .001
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Unfortunately, fewer than 10% of the men in the final weighted sample lived in the
regions of Appalachia. Table 3 below includes the weighted percentages for demographic and
other factors showing the differences between Appalachian and Non-Appalachian men. Even
though variables with very small numbers of valid responses typically yield unreliable estimates,
it is noteworthy that a larger proportion of Appalachian men (61.32%) reported never discussing
the shared-decision-making topics than Non-Appalachian men (46.65%). However, based on
Chi-squared tests of independence there are no statistically significant differences (p-value <
0.05) between these two groups.
Table 3
Demographics and Other Comparisons between Appalachian and Non-Appalachian Men
Variables

Appalachian (n=58)

Non-Appalachian (n=719)

Weighted

Standard

Weighted

Standard

%

Error of %

%

Error of %

Ages 50-69 years

89.87

4.67

83.34

1.67

non-Hispanic White

81.06

9.36

67.64

2.08

Married or Cohabiting

75.56

7.79

71.05

2.22

> High School Education

59.16

10.54

66.21

2.09

Employed

49.68

10.26

45.44

2.65

Household Income ≥ $50,000

55.77

9.23

55.70

2.67

Health Insurance

79.00

8.85

89.62

1.45

Regular Provider

72.53

10.66

72.83

2.54

Recent Visit

82.60

7.94

83.74

1.71

YES - Had a PSA Test

60.23

10.35

64.12

2.67

Never Discussed 4 SDM Issues

61.32

8.32

46.65

3.01

66

Descriptive Data on PSA Testing and Other Covariates
Sixty-four percent of the men reported ever having a PSA test. One in three black men
40-49 years ever had a PSA test. Fifty-two percent of the men 50-59 years old and more than
75% of all men 60 years and older reported ever having a PSA test. The rates of PSA testing
differed between men in the different age groups. Older men were more likely to have had a
PSA test. For example, men in the 60-69 and 70-75 age categories were significantly more
likely to have obtained a PSA test than men in the 50-59 years age group (Unadjusted ORs =
3.00; CI = 1.94-4.63; OR = 5.05; CI = 2.65-9.16 respectively).
White men had the highest rates of PSA testing, but these rates were not statistically
significantly different from men of other race or ethnic groups. Men who were married or living
as married had significantly higher PSA testing rates than other men. These differences were
significant 2 (49, n=751) = 21.74, p < 0.0001. In fact, these men were three times more likely
to obtain PSA test than men who were not married or cohabiting (Unadjusted OR = 2.99; CI =
1.90 - 4.70). Screening rates were higher in men with more than a high school level of education
than among men with a high school education or lower education level (2 (49, n=758) = 9.19, p
= 0.004). Men with some college, bachelor‟s, or higher degrees were more likely to obtain
screening than men a high school education (Unadjusted ORs = 2.12, CI = 1.19 – 3.79; OR=
2.60 CI = 1.22-5.52; OR = 4.79; CI = 2.34-9.79 respectively). Retired men were three times
more likely to have had a PSA test than working men (Unadjusted OR = 3.16; CI = 1.77-5.65).
Men in the lowest income bracket were more than two to four times less likely to obtain
screening than all higher income groups with unadjusted odds ratios and confidence intervals
ranging from 2.26 to 3.99 and 1.02 to 7.99 respectively. See Table 2.
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The percentage men with medical insurance with history of PSA testing was significantly
higher than men with no insurance (2 (49, n=750) = 7.22, p = 0.009). Men who reported having
a regular provider or medical home also had significantly higher rates of PSA testing than men
who did not have a medical home; (2 (49, n=744) = 17.83, p = 0.0001). The percentage of men
who had a PSA test was also higher among those who reported at least one medical visit within
the past 2 years than men who did not have a visit within the past 2 years (2 (49, n=758) =
16.87, p = 0.0002). See Table 4. These figures represent crude associations and are unadjusted
for other covariates that are addressed in subsequent regression models.
Health Care Use and Health Status
Seventy four percent of the men reported having a regular medical provider and about
83% reported having had at least one medical visit within the past 2 years. In terms of their
general health status, 40% of men rated their health as very good or excellent, 41% rated their
health as good, and just below 20% rated their health as fair or poor. The number of chronic
medical conditions reported by survey respondents ranged from 0 to 7 conditions (M = 1.69,
Standard Error = 0.08; 95% CI = 1.53 – 1.86). Twenty two percent reported having no chronic
medical problems. About 50% reported having either one or two medical conditions, and 28%
reported having three or more chronic medical problems. See Table 3.
Risk Perception and Attitude Toward Cancer Screening
In terms of absolute cancer risk perception 36 % of men indicated that they felt they were
likely or very likely to get cancer in their lifetime; 42% indicated that they were neither unlikely
nor likely to get cancer; and 22% percent indicated that they felt unlikely or very unlikely that
they would get cancer in their lifetime. Over 40 % of men sampled indicated that they agreed or
strongly agreed that they would rather not know their chances of having cancer (not specific to
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prostate cancer). Approximately 57% of men surveyed stated that they disagreed or somewhat
disagreed that some cancers were slow growing and needed no treatment. There was a negative
association with prostate cancer screening for men who indicated that they strongly or somewhat
agreed that some cancers were slow growing and needed not treatment (Unadjusted OR = 0.47;
CI = 0.30 - 0.74). There were no significant differences by race or by region.
Table 4.
Weighted Percentages for Health Care Utilization, Health Status and Medical problems
Variables

Total Sample

Ever Had PSA

Never Had PSA

N=777

n=503

n=258

n

Weighted %

n

Weighted%

n

Weighted%

Health Insurance**

671

88.91

458

67.12

198

32.87

Regular Health Provider***

568

73.52

413

70.80

144

29.20

Recent Medical Visit***

652

83.47

456

69.15

183

30.85

Poor

27

4.33

15

3.33

12

6.07

Fair

108

14.17

52

12.35

56

17.37

Good

286

41.22

185

38.77

101

45.53

Very Good

244

31.14

181

34.79

63

24.71

Excellent

76

9.15

56

10.75

20

6.33

0 medical problems

156

22.48

84

16.94

72

32.35

1 or 2 medical problems

259

48.97

253

53.85

106

40.28

3 or more medical problems

206

28.54

137

29.21

69

27.36

Other Variables

Health Status*

Chronic Medical Problems*

Within Group Differences based on Chi Square Analyses: ** p < .01; *** p < .001
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Outcomes of Research Questions
Research Question 1. How do older adult male patients rate their perceptions of the quality of
their care and communication with their health provider?
Figure 11 shows the racial variations in the percentages of men who rated their perceived
quality of care as very good or excellent, good, or fair or poor. Overall, 58% to 84% of men
perceived the quality of the care they received as very good or excellent. Significantly more
Non-Hispanic white men rated their perception of quality of care higher (very good or excellent)
than men of other races based on Chi squares analysis (2 (49, n=635) = 7.23, p = 0.0098). On
the other hand Hispanic men rated their perceptions of quality of care significantly lower than
men of other races (2 (49, n=635) = 5.42, p = 0.024).
90%
84%

81%

80%
73%
70%
60%

58%

50%
40%
30%
20%

19%

22%
17%
11%

10%

10%
6%

12%
7%

0%
Hispanic

Non-Hispanic White
VeryGood or Excellent

Non-Hispanic Black
Good

Fair or Poor

Figure 11. Ratings for Perceived Quality of Care by Race
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Other or Unidentified

There was some variation in the ratings men had for their interactions with their providers
on the individual provider-patient interaction questions or scale. See Figure 12. There were no
statistically significant racial or regional differences in these ratings or percentages. However
there were significant differences in proportions between men who previously had a PSA test
and those who reported that they never had a PSA test based on Chi Square tests. A significantly
higher percentage of men who ever had a PSA indicated that their provider always helped deal
with feelings of uncertainty about their health or health care (2 (49, n=604) = 7.30, p = 0.0094);
spent enough time with them (2 (49, n=599) = 6.92, p = 0.011); and explained things in a way
they could understand, (2 (49, n=611) = 4.16, p = 0.046). There were marginally significant
differences for ensuring they understood the things needed to do to take care of their health (2
(49, n=614) = 3.15, p = 0.082) and being given the chance to ask all their health-related
questions (2 (49, n=618) = 3.86, p = 0.055). See Figure 12. The seven items for general patient
provider communication were summed. Scores ranged from a minimum of 7 to a maximum of
28. Average score for summated scale measuring provider patient communication was 23.63
(SE = 0.25; 95% CI = 23.11 – 24.14).
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58%

Gave them the chance to ask all their healthrelated questions†

71%

39%

Gave them the attention they needed
regarding their feelings and emotions

46%

50%

Involved them in decisions about their
health care as much as they wanted

59%

Ensure they understood the things they
needed to do to take care of their health†

53%

Explained things in a way they could
understand*

53%

64%

64%

36%

Spent enough time with them*

52%

32%

Helped deal with feelings of uncertainty
about their health or health care **

48%
0%

Never Had PSA

10% 20% 30% 40% 50% 60% 70% 80%

Ever Had PSA

Within group differences based on Chi Square Analyses: ** p < .01; *** p < .001
Figure 12. Percent of men giving a rating of „Always‟ for Provider-patient communication by
PSA Screening
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Research Question 2. To what extent are health providers engaging in shared-decision- making
process by discussing prostate cancer screening according to the most recent national screening
guidelines?
This analysis provided the self-reported rates on if health providers were discussing
prostate cancer screening, whether men wanted to be screened, as well as the implications, pros,
and cons of prostate cancer screening. Table 4 shows the weighted percentages of the number of
positive responses to the seven questions assessing for the total sample and for men who reported
having a nonemergency primary care visit within the past two years. Scores for the variable
shared-decision making (Q4 through Q7) ranged from 0 to 4 (Mean = 1.18; Standard Error =
0.08; 95% CI = 1.02 – 1.33).
Table 5 illustrates that 64% of the total men sampled reported having ever had a PSA
test. Fifty six percent stated that they discussed the screening with their doctors and over 80% of
the men stated that in that conversation the doctor or health provider asked them if they wanted
to have the test done. When asked if the doctor or health provider ever discussed the other four
key issues regarding PSA testing, comparatively few men reported ever discussing these issues
with their health provider (See Table 5, Q4 through Q7). Less than one in four men reported that
a physician or health provider ever told them that some experts disagree about whether men
should have a PSA test. Just over 30% indicated ever being told that the PSA test is not always
accurate or that some prostate cancers are slow growing and do not need treatment. However,
about 40% of the respondents indicated that they were told that prostate cancer treatment can
cause problems with urination and having sex. These figures were similar among men who
reported having had a nonemergency medical visit within the past 2 years as shown in Table 5.
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Table 5
Weighted Percentages of Yes Responses to the Shared-Decision-Making Questions (N=777)

Questions about PSA testing
Q1. Have you ever had a PSA test?

Total

Primary Visit

Sample

in 2 years

(N=777)

(n=625)

% (n)

% (n)

64.21 (503)

69.21 (458)

56.13 (441)

61.22 (401)

83.84 (357)

83.97 (327)

21.05 (171)

23.73 (158)

29.32 (232)

32.26 (208)

28.25 (222)

30.75 (198)

38.55 (295)

40.98 (258)

Q2. Has a doctor or health provider ever discussed with you
whether or not you should have the PSA test?
Q3. In that discussion, did the doctor or health provider ask you
whether or not you wanted to have the PSA test?
Q4. Did a doctor or health provider ever tell you that some
experts disagree about whether men should have PSA tests?
Q5. Has a doctor or health provider ever told you that the PSA
test is not always accurate?
Q6. Has a doctor or health provider ever told you that some
types of prostate cancer are slow-growing and do not need
treatment?
Q7. Has a doctor or health provider ever told you that treating
any type of prostate cancer can lead to serious side-effects,
such as problems with urination or having sex?
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Bivariate analyses using Cross-tabulations with Chi squares showed that there were no
statistically significant effects by race or ethnicity, or region. However, from Figure 13 we can
see the same trend as described above. Non-Hispanic black men had lower screening rates than
white or Hispanic men and fewer reported having discussed prostate cancer screening.
However, among those who reported having a discussion Non-Hispanic black men were the
largest percentage of men reporting that they were asked if they wanted to have the PSA test.
100%
93%
88%
84%

82%

84%
80%

80%
68%
64%
60%

64%
55%

62%
54%

56%

58%
55%

54%
51%

51%

40%

20%

0%
Ever had a PSA test?
Total

Non-Hispanic White

Dr discussed with you whether
you should have PSA test?
Non-Hispanic Black

Hispanic

In that discussion, did Dr ask you
whether you wanted to have test?
Other Race

Appalachia

Figure 13: Frequencies of Positive Responses about PSA Testing By Race & Region
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More Non-Hispanic white men reported having been told by their doctor or health
provider that some experts disagree about PSA testing, that the PSA test is not always accurate
and that some cancers are slow growing and do not need treatment when compared to NonHispanic black men. A more detailed description of the responses to these questions is provided
in Figure 14 below.
50%
43%
39% 39%
39%

40%
33%
31%
29%

30%

28%

31%
27%
25%

21%

22%

22%

22% 22%

20%

20%

19%
15%

21%

19%

19%
17%

16%

10%

0%
Some experts disagree
about PSA testing
Total

PSA test is not always
accurate

Non-Hispanic White

Some PCAs are slow- Treating PCA can lead to
growing and do not need problems with urination
treatment
or sex

Non-Hispanic Black

Hispanic

Other Race

Appalachia

Figure 14: Frequencies of Positive Responses about PSA Testing By Race & Region
The number of Appalachian respondents was small and consequently most analyses
including the Appalachian variable lacked statistical power; however, men living in the
Appalachian region were less likely to report having had these discussions than men from other
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regions. In general, based on Figures 13 and 14 that describe the proportions of positive
responses to questions about PSA testing, we can see the same general trends as described above.
Research Question 3. What factors are associated with shared-decision making about PSA
testing?
The predictors showing a significant linear association with whether men discussed the
key areas for shared decision making about PSA testing are included in Table 6. Age, household
income, having a regular provider level of communication and having had a recent medical visit
were significant positive predictors of shared-decision making. Men who strongly agreed that
they would rather not know their chances were less likely to engage in shared-decision making
than men who preferred to know their chances of getting cancer. These variables accounted for
approximately 12% of the variance in shared-decision making.
Table 6.
Multiple Linear Regression Estimates for the Predictors of Shared-Decision Making (n = 457).
Variables

Estimate

SE

t-value

p-value

Age

0.39

0.16

2.42

0.02

Household income

0.04

0.02

2.16

0.04

Regular Provider

0.41

0.19

2.15

0.04

General Communication

0.03

0.01

2.21

0.03

-- 0.37

0.18

-2.04

0.05

0.61

0.21

2.90

.001

Rather not Know
Recent Visit
R2 (R Squared)

0.12

F

8.54
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<.0001

Research Question 4. What is the relationship between male patient’s perceptions of the quality
of their care, provider patient discussion about prostate cancer and PSA testing?
The results of four separate multiple logistic regression models used to estimate the
strength of the association of the various predictors of PSA testing in the sample are reported in
Table 7. Model one examined demographic factors such as age (10-year category), marital
status, race or ethnicity, education level, and other correlates such as perception of cancer risk,
number of chronic medical problems, perceived quality of care received, having a regular
provider, and having had a medical visits in the past 2 years. As expected age was a significant
predictor of PSA testing in this model and across all four models (ORs ranged from 2.51 – 2.97).
For every 10-year increase in age the likelihood of having a PSA test increased by 2.5 times to
2.97 times. Men who were married or living as married were twice as likely to have obtained
PSA testing (OR = 2.41 95% CI = 1.21 – 4.80) when compared to men who were not cohabiting.
Having had a nonemergency medical visit in the past 2 years positively predicted PSA testing
(OR 4.41; 95% CI = 1.57 – 12.42). Higher perception of quality of care was a significant
predictor of PSA testing. However, men who indicated that they would rather not know if they
had cancer were less likely to have obtained screening compared to men who cared to know (OR
= 0.49; 95% CI = 0.28 – 0.85).
The variable addressing the four key questions about pros and cons of prostate cancer
screening that define shared-decision making was added in model 2. Discussions of the four key
controversial issues related to shared-decision making positively predicted prostate cancer
screening. For a one unit increase in level of discussion of key issues the odds of having had a
PSA test (versus not having a PSA test) increases by a factor of 3.35. Age, education level,
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married or cohabiting, and perceived quality of care remained positive predictors of PSA testing
in this model.
Model 3 examined the effect of general discussion about PSA testing while controlling
for the other variables. The strongest predictor of PSA testing was the doctor or health provider
having ever discussed whether the respondent should have the PSA test. Men whose doctor
talked with them about PSA testing were 69.5 times more likely to have had the PSA test
compared to men who indicated that they had not ever discussed PSA testing with their doctor
(OR = 69.45; CI = 23.60 – 204.61). Age (OR = 2.51; CI =1.16 – 5.45), having more than a high
school education (OR = 3.61; CI = 1.17 – 11.17), and quality of care (OR = 1.83; CI = 1.01 –
3.31) remained significant predictors of PSA testing in this model.
In model 4 when the shared-decision making variable was added patients who discussed
general PSA testing were only 47 times more likely to obtain prostate cancer screening with the
PSA test (OR = 47.42; CI = 14.91 – 150.74). Shared-decision making also significantly
predicted PSA testing (OR = 47.42; CI = 14.91 – 150.74). In other words, both variables
predicted PSA testing but discussing the four key issues required for shared-decision making
significantly modified the effect of having a general talk about prostate cancer screening. Age
(OR = 2.66; CI =1.14 – 6.24), having more than a high school education (OR = 4.01; CI = 1.14–
14.18) and quality of care (OR = 2.04; CI = 1.10 – 3.78) also remained significant predictors of
PSA testing in the fourth model.
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Table 7
Logistic Regression Estimates for the Predictors of PSA Testing
Model 1

Model 2

Model 3

Model 4

(n = 437)

(n = 427)

(n = 437)

(n = 427)

Estimate (95% CI)

Estimate (95% CI)

Estimate (95% CI)

Estimate (95% CI)

Age (10-year increase)

2.67 (1.44 – 4.95)*

2.97 (1.56 – 5.65)**

2.51 (1.16 – 5.45)*

2.66 (1.14 – 6.24) *

Married or Cohabiting =1

2.41 (1.21 – 4.80)*

3.44 (1.52 – 7.79)*

2.11 (0.81 – 5.56)

2.84 (0.94 –8.58) †

> High School =1

2.05 (1.06 – 3.95)*

2.39 (1.08 – 5.28)*

3.61 (1.17 – 11.17)*

4.01 (1.14–14.18)*

Quality of Care

1.63 (1.15 – 2.32)*

1.91 (1.23 – 2.95)*

1.83 (1.01 – 3.31)*

2.04 (1.10 – 3.78)*

Rather not know = 0

0.49 (0.28 – 0.85)*

0.51 (0.23 – 1.10)

0.65 (0.22 – 1.90)

0.70 (0.19– 2.66)

Recent Visit =1

4.41 (1.57 – 12.42)*

3.80 (0.93 – 15.48) †

3.16 (0.90 – 11.13)†

3.29 (0.90 –12.01) †

Covariates

Shared-decision

3.35 (1.94 – 5.80)***

1.93 (1.11 –3.56)*
69.49 (23.60 – 204.61)*** 47.42 (14.91 – 150.74)***

Dr. Discussed PSA
Testing =1
Note: *p < .05; ** p < .01; *** p < .001; †p < .10
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CHAPTER 5
DISCUSSION
The recommendations for use of the PSA test have been modified over the years as new
scientific evidence emerged making it necessary to continually evaluate the impact of these
evidence based recommendations on medical and public health practice and on the lives and
health of the population. Even though prostate cancer is the second leading cause of cancer
deaths in men after lung cancer and has a higher mortality rate than many other types of cancer
the controversy relating to early detection and the efficacy of PSA screening remains unrelenting
(Barry, 2009; Slatkoff et al., 2011). The most current prostate cancer screening
recommendations discourage wide spread PSA screening for men at low to average risk but
encourages shared-decision making between adult men and their health providers regarding the
possible benefits and risks of PSA testing and gives guidelines for what topics are to be included
in shared-decision making (Carter et al., 2013; Moyer, 2012). This study assessed men‟s
perceptions of the quality of care and the level of communication they have with their health
providers, the extent to which these recommendations are being followed, and what factors are
associated with shared-decision making and PSA testing in a nationally representative sample.
Perceptions of Communication with Health Providers and Quality of Care
In general, most men rated their general communication with their health providers as
very good or excellent. There were no demographic or regional differences in these ratings.
However, men who had a previous PSA test were more likely to rate their level of
communication higher than men who did not have a PSA test. This association is supported by
previous research that suggests that higher quality communication that is patient-centered, that
addresses concerns, and that helps patients to feel respected and understood leads to more
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informed health decisions, improves adherence to medical recommendations, and helps patients
deal with existing or potential medical conditions (Epstein & Street, 2011; Ha & Longnecker,
2010; Politi, Lewis, & Frosch, 2013; Zolnierek & Dimatteo, 2009). This suggests that there may
be a need for additional to investigate what can be done to facilitate better communication
among the men who give a lower rating for their level of communication or if there were other
factors that prompted their poorer rating.
Among the men who never had a PSA test only about one third indicated that the
provider always spent enough time with them or helped them deal with their feelings of
uncertainty about their health. This finding might be suggesting, as did some previous research,
that patients feel rushed in their medical encounters that may not provide enough time for them
to address their issues and concerns about their health. This also impacts the patients‟ ability to
develop a trusting relationship that in turn impacts overall patient satisfaction ratings
(Dugdale, Epstein, & Pantilat, 1999; Fiscella et al., 2004).
Hispanic men rated their quality of care lower than men of other races. Previous research
indicates that Hispanics in America are faced with a number of barriers to culturally and
linguistically appropriate care in some areas. These barriers may include issues with lower
socioeconomic factors that might impact health care use, language proficiency, and other
communication factors, as well as other sociocultural factors (Escarce & Kapur, 2006; Gast &
Peak, 2012). Continued efforts are needed to identify and address the conditions that negatively
impact quality of care and the poorer health outcomes experienced by minority men.
Prevalence and Predictors of PSA Testing
In this study the percentage of men who reported ever having a PSA test is comparable to
data from other national samples (Finney Rutten et al., 2005; Hoffman et al., 2009). As
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expected, older men were more likely to report ever having had a PSA test. The strongest
predictor of PSA testing was having had a discussion about testing with their physician.
Education and being married or cohabiting were also significant predictors of PSA, which is
consistent with previous reports on predictors of prostate cancer screening (Emerson et al., 2009;
Finney Rutten et al., 2005).
Another factor associated with PSA testing was men‟s perception of the quality of care
received. This was highly correlated with level of general communication with the health
provider but this separate variable was a strong independent predictor of PSA testing even when
regression models were adjusted for other factors. In other words, men who rated the quality of
their care high were much more likely to have obtained the PSA test than men who had lower
ratings for quality of care. Lee and colleagues (2012) reported poor quality of care as a barrier to
prostate cancer screening in urban dwelling African American and Afro-Caribbean men.
There are still a significant number of men who did not want to find out if they had
cancer and this was negatively associated with PSA testing. This finding supports previous
research that indicates that men who fear cancer or the implications of a prostate cancer
diagnosis may be less likely to obtain screening (Friedman et al., 2009; Ukoli et al., 2013).
Prevalence and Factors Associated with Shared-Decision Making
About 60% of the men in the study who had a preventive health visit in the past 2 years
reported having discussed PSA testing with their health provider. However, in these 2 years post
the updated USPSTF recommendations approximately only 2 to 4 out of 10 men in the
recommended age for screening for prostate cancer report having ever been told by their health
provider that some experts disagree about whether men should have PSA tests, that the PSA test
is not always accurate, some cancers are slow growing and do not need treatment, or that prostate
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cancer treatment can lead to serious sexual and urinary side effects. These are the four key
issues that national health organizations indicate must form part of the discussion necessary to
facilitate shared- or informed-decision making. While a provider recommendation of a PSA test
was the largest predictor of screening, discussing these issues had a substantive moderating
effect on screening. In other words, discussing the controversial issues reduces the likelihood of
PSA testing among older adult men. This finding suggests that more work needs to be done to
encourage shared-decision making about prostate cancer screening in the clinical setting. It is
understood that health providers are constrained for time in individual clinical encounters but it
might be useful to identify other ways of communicating accurate and balanced information
regarding PSA testing in that setting.
One unanswered question derived from this finding concerns the nature of discussions
and topics covered among the men who report having discussed prostate cancer screening with
their health provider. In this study between 51% and 58% of men of all races reported having
ever discussed PSA testing with their health provider, but most men indicated that they had not
engaged in shared-decision making with their providers. It is likely that physicians are
continuing to order PSA tests without informing their patients about the pros and cons of
screening and engaging in the shared-decision making process as recommended as reported
previously (Ferrante et al., 2011; Hoffman et al., 2009; Wilkes et al., 2013). Shared-decision
making allows health providers to work in partnership with their male patients in a way that
promotes their autonomy to make decisions about their health that is informed by the best
available evidence, their personal beliefs and preferences, and which provides accurate
information on all options available (Elwyn et al., 2010; Frosch, 2012). Because of the potential
risks associated with prostate cancer screening such as false positives that can lead to undue
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stress, unnecessary biopsies of the prostate that can in turn lead to unwanted side effects, it is
necessary to have these discussions so that men can come to terms with the implications and
consequences of their decision to screen or not screen. Failure to have these discussions robs
men of the opportunity to have their fears and concerns about screening addressed by their
provider (Charles, Gafni, & Whelan, 1997). While this does not necessarily mean that because
men are not having these discussions with their providers that they are completely uninformed
about issues regarding PSA testing as there are other sources of information. However, previous
studies suggest that this sometimes leads to misinformation and lack of preventive health
screenings based on inaccurate or incomplete information (Ferrante et al., 2011).
Limitations
The HINTS survey did not provide data on whether men were asymptomatic for prostate
cancer or other prostatic diseases. Other benign prostate conditions might prompt physician visits
and could signal need for prostate examinations and prostate cancer screening (Cunningham &
Kadmon, 2013; McVary et al., 2011; Paolone, 2010). The data also did not measure intent to
obtain screening nor whether the discussion with the physician specifically influenced their
decision to screen or not to screen. This information would have been useful to help delineate
reasons for obtaining or refusing prostate cancer screening.
The Appalachian region had the highest nonresponse rate to the survey. Consequently
the number of Appalachian male respondents is small and even with the sample weighting could
lead to potential errors in statistical estimates because the respondents may not accurately
represent Appalachian men in the national population. Future studies or subsequent iterations of
HINTS should include methods to increase sample size for Appalachian residents in populationbased studies.
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More generally, cross-sectional studies do not reflect changes in the phenomena being
studied over time and are therefore limiting in inferring causation. However, this study estimates
the prevalence of shared-decision making in a nationally representative sample at this point in
time. Future time series designed studies can use these questions and variables to determine
trends in shared-decision making about prostate cancer screening as the USPSTF
recommendations and the recommendations of the other guiding organizations become more
widely distributed.
Implications and Recommendations for Future Research
The majority of studies examining discussions about PSA testing were conducted prior to
the most recent (2011) national screening recommendations. This study adds to the literature
that examines the impact of public policy decisions on prostate cancer screening on provider
interactions with adult male patients and their screening decisions. These decisions will
consequently impact future prostate cancer incidence rates. Just as increased use of the PSA test
in the 1990s led to significantly higher incidence rates of prostate cancer, it is expected that
reduced screening rates will lead to fewer prostate cancers being detected. Even though there are
likely to be decreased incidence rates nationally, this outcome may lead to a false sense of
success in prostate cancer prevention, screening, and treatment. It is therefore imperative that
the clinical, epidemiological and behavioral research is continued to further reduce the burden of
this disease and the existing disparities.
This evidence shows that most health providers are not following the recommended
screening guidelines and are not discussing important issues that impact men‟s decisions to be
screened, which suggests that there is a need for various types of interventions to improve these
numbers in the clinical setting. This information might help inform the design of more effective
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provider based interventions to increase shared-decision-making about PSA testing and increase
facilitation of PSA screening, if screening is recommended and desired by older adult males.
Additionally, interventions at the community level to increase knowledge about prostate cancer
and the benefits and risks of screening as well as how to initiate these discussions with their
health provider may increase the likelihood of shared-decision making in the clinical setting.
In addition it may be useful to evaluate the feasibility of using trained prostate cancer
health or nurse educators in the clinical setting to provide accurate information on the pros and
cons of prostate cancer screening. Making decisional aids and checklists readily available to
men (wherever they seek health information) to help them determine their prostate cancer risk
along with questions to ask their provider may help boost the shared-decision making process.
Further to this, it would be useful to identify and include other approaches that might lessen the
perils associated with screening. Hayes and Barry (2014) indicate that having a PSA test every 2
years instead of annually, increasing the PSA level that would trigger a biopsy as well as
providing less aggressive treatment for newly diagnosed prostate cancer cases may be options to
consider. Future studies could also examine the impact that this type of medical and scientific
skepticism has on patient decision making as suggested by Politi and colleagues (2011).
These findings may be used to increase public awareness, education, and screening about
this critical public health the disease. If we are to make similar strides in prostate cancer as we
have done in breast and cervical cancer screening and outcomes, early detection may still be one
of the most critical issues. Improvements in prostate cancer education, screening methods, along
with more effective and efficacious treatment modalities will increase the chances of a successful
outcome.
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Conclusion
Overall most men reported very good or excellent overall communication with their
health provider and indicated satisfaction with the quality of care they received. However,
Hispanic men reported lower perceptions of quality of care than men of other races and nonHispanic white men reported the highest ratings for quality of care received. Quality of
provider-patient communication and quality of care received were associated with PSA testing
and with shared-decision making. Age, marital status, and level of education were also
significant predictors of PSA testing. While having a discussion with a doctor about PSA testing
was the biggest independent predictor of PSA testing, the effect was significantly modified when
those discussions included information that some experts disagreed with PSA testing, that the
test may not always be accurate, that some prostate cancers are nonaggressive and do not need
treatment, or that prostate cancer treatment can lead to serious sexual and urinary side effects.
Even though a majority of older adult men received the PSA test and reported good providerpatient communication, only a marginal number reported having discussed the pros and cons of
prostate cancer screening with their health providers. This means that health providers are
falling short of the USPSTF recommendation for the use of the PSA test in the clinical setting
and may be continuing to order the PSA test as part of routine testing for older adult men.
Consequently, there is need for continued efforts to increase awareness of prostate cancer and
PSA testing in the clinical and community setting so that men can be equipped to make informed
decisions about prostate cancer screening and be able to initiate these discussions with their
providers. Until more rigorous scientific evidence becomes available, these challenges will
continue as patients, providers, researchers, advocates, and other stakeholders deal with this
important health concern.
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APPENDIXES
APPENDIX A
Historical Achievements in Prostate Cancer Research & PSA Testing
The following list includes some important dates in the study and treatment of prostate cancer
and the development and use of PSA test as presented by Denmeade & Isaacs (2002).
1. 1904 – Hugh Hampton Young from Johns Hopkins develops the radical prostatectomy
2. 1913 – Prostate Cancer is treated with direct implantation of radium into the prostate
3. 1936 – Ethel Gutman describe elevated acid phosphatase activity in prostate cancer
4. 1938 – Robert Moore and Allister McLellan use oestrogen injections for medical castration
5. 1941 – Charles Huggins reports on the beneficial effects of castration and oestrogen in men
with advanced prostate cancer
6. 1947 – Terrence Millin introduces radical retropubic prostatectomy
7. 1962 – Malcolm Bagshaw describes megavoltage radiation for localized prostate cancer
8. 1966 – The Gleason Grading system is developed
9. 1971 – The National Prostatic Cancer project is initiated (completed in 1988)
10. 1973 – The Veterans Administration Study (VACURG) shows the benefit of hormonal
therapy
11. 1975 – WW Scott and colleagues report the results of the first national randomized
chemotherapy study for prostate cancer
12. 1980 – Prostate-specific antigen is found to be elevated in serum of men with prostate
cancer
13. 1980-1984 – in 1980‟s PSA was determined to be more sensitive for detecting prostate
cancer than DRE but less specific
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14. 1981 – Luteinizing hormone-releasing hormone analogues are first used to treat prostate
cancer
15. 1983 – Patrick Walsh reports on nerve-sparing prostatectomy to preserve erectile function
16. 1983 – H. Holm develops ultrasound guided trans perineal implantation of radioactive seeds
17. 1985 – Leuprolide is approved by the Food and Drug Administration (FDA) for treatment
of Prostate cancer
18. 1986 – FDA approves the use of the PSA for monitoring prostate cancer
19. 1988 – Ultrasound biopsy device is developed
20. 1989 – Flutamide receives FDA approval
21. 1990 – Three dimensional conformal radiation therapy is developed
22. 1994 – FDA approves PSA screening for the detection of early prostate cancer
23. 1995 – A meta-analysis trial of combined androgen blockade concludes that no significant
benefit is achieved by combining these drugs
24. 1997 – Randomized studies show the benefits of combining radiation and androgen ablation
(Denmeade & Isaacs, 2002)
25. 2008 – The USPSTF recommends against PSA-based screening for prostate cancer in men
aged 75 years and older and concluded that the evidence was insufficient to make a
recommendation in younger men
26. 2009 – Reports from two major randomized controlled studies published in New England
Journal of Medicine
27. 2011 – The USPSTF recommends against PSA-based screening for prostate cancer in all age
groups.
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APPENDIX E
Health Information National Trends Survey Questions
A7.

Overall, how confident are you that you could get advice or information about cancer if
you needed it? (CancerConfidentGetHealthInf )
1. Completely confident
2. Very confident
3. Somewhat confident
4. A little confident
5. Not confident at all

Questions on Healthcare Utilization
C1.
Not including psychiatrists and other mental health professionals, is there a particular
doctor, nurse, or other health professional that you see most often (1= Yes; 2 = No)?
(RegularProvider)
C2.
Do you have any kind of health care coverage, including health insurance, prepaid plans
such as HMOs or government plans such as Medicare (1= Yes; 2 = No)?
(HealthInsurance)
C3.
About how long has it been since you last visited a doctor for a routine checkup? A
routine checkup is a general physical exam, not an exam for a specific injury, illness, or
condition. (MostRecentCheckup)
1. Within past year (anytime less than 12 months ago)
2. Within past 2 years (1 year but less than 2 years ago)
3. Within past 5 years (2 years but less than 5 years ago)
4. 5 or more years ago
5. Don't know
6. Never
C4.
In the past 12 months, not counting times you went to an emergency room, how many
times did you go to a doctor, nurse, or other health professional to get care for yourself?
(FreqGoProvider)
1. 0 None GO TO D1 on the next page
2. 1 time
3. 2 times
4. 3 times
5. 44 times
6. 5-9 times
7. 10 or more times
C5.
The following questions are about your communication with all doctors, nurses, or other
health professionals you saw during the past 12 months. How often did they do each of
the following: 1 =Always; 2=Usually; 3= Sometimes; 4= Never
1. Give you the chance to ask all the health-related questions you had?
(ChanceAskQuestions)
2. Give the attention you needed to your feelings and emotions? (FeelingsAddressed)
3. Involve you in decisions about your health care as much as you wanted?
(InvolvedDecisions)
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C6.

C7.

4. Make sure you understood the things you needed to do to take care of your health?
(UnderstoodNextSteps)
5. Explain things in a way you could understand? (ExplainedClearly)
6. Spend enough time with you? (SpentEnoughTime)
7. Help you deal with feelings of uncertainty about your health or health care?
(HelpUncertainty)
In the past 12 months, how often did you feel you could rely on your doctors, nurses, or
other health care professionals to take care of your health care needs?
(DrTakeCareNeeds)
Overall, how would you rate the quality of health care you received in the past 12
months? (QualityCare)

Questions on Overall Health
F1. In general, would you say your health is (GeneralHealth)
1. 1 Excellent
2. 2 Very good
3. 3 Good
4. 4 Fair, or
5. 5 Poor?
F2.
Overall, how confident are you about your ability to take good care of your health?
(OwnAbilityTakeCareHealth)
1. 1 Completely confident
2. 2 Very confident
3. 3 Somewhat confident
4. 4 A little confident
5. 5 Not confident at all
F3. Has a doctor or other health professional ever told you that you had any of the following
medical conditions: 1= Yes; 2=No
1. Diabetes or high blood sugar? (MedConditions_Diabetes)
2. High blood pressure or hypertension? (MedConditions_HighBP)
3. A heart condition such as heart attack, angina, or congestive heart failure?
(MedConditions_HeartCondition)
4. Chronic lung disease, asthma, emphysema, or chronic bronchitis?
(MedConditions_LungDisease)
5. Arthritis or rheumatism? (MedConditions_Arthritis)
6. Depression or anxiety disorder? (MedConditions_Depression)
Questions on Screening for Prostate Cancer Using PSA Test
The following questions are about discussions doctors or other health care professionals may
have with their patients about the PSA test that is used to look for prostate cancer.
L8.
Have you ever had a PSA test? (EverHadPSATest) 1 = Yes; 2 = No
L9.
Has a doctor ever discussed with you whether or not you should have the PSA test?
(DrShouldPSATest ) 1 Yes; 2 No GO TO L11 below
L10. In that discussion, did the doctor ask you whether or not you wanted to have the PSA
test? (DrWantedPSATest) 1 Yes; 2 No
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L11.
L12.

Did a doctor ever tell you that some experts disagree about whether men should have
PSA tests? (SomeDisagreePSATests) 1 Yes; 2 No
Has a doctor or other health care professional ever told you that:
a. The PSA test is not always accurate? (ProstateCa_PSATest) 1 Yes; 2 No
b. Some types of prostate cancer are slow-growing and need no treatment?
(ProstateCa_SlowGrowing) 1 Yes; 2 No
c. Treating any type of prostate cancer can lead to serious side-effects, such as
problems with urination or having sex? (ProstateCa_SideEffects) 1 Yes; 2 No

Questions on Cancer History
M1. Have you ever been diagnosed as having cancer? (1= Yes; 2 = No) No GO TO N1 on the
next page. (EverHadCancer)
M2. What type of cancer did you have? Mark all that apply.
a. Bladder cancer (CaBladder)
b. Bone cancer (CaBone)
c. Breast cancer (CaBreast)
d. Cervical cancer (cancer of the cervix) (CaCervical)
e. Colon cancer CaColon
f. Endometrial cancer (cancer of the uterus) (CaEndometrial)
g. Head and neck cancer (CaHeadNeck)
h. Hodgkin's lymphoma (CaHodgkins)
i. Leukemia/Blood cancer (CaLeukemia)
j. Liver cancer (CaLiver)
k. Lung cancer (CaLung)
l. Melanoma (CaMelanoma)
m. Non-Hodgkin lymphoma (CaNonHodgkin)
n. Oral cancer (CaOral)
o. Ovarian cancer (CaOvarian)
p. Pancreatic cancer (CaPancreatic)
q. Pharyngeal (throat) cancer (CaPharyngeal)
r. Prostate cancer (CaProstate)
s. Rectal cancer (CaRectal)
t. Renal (kidney) cancer (CaRenal)
u. Skin cancer, non-melanoma (CaSkin)
v. Stomach cancer (CaStomach)
w. Other-Specify (CaOther_OS CaOther Cancer_Cat)
M3.

At what age were you first told that you had cancer? (WhenDiagnosedCancer)

Survey Questions on Beliefs about Cancer
Think about cancer in general when answering the questions in this section.
N1.
How likely are you to get cancer in your lifetime? (ChanceGetCancer)
1 = Very unlikely; 2 = Unlikely; 3 = Neither unlikely nor likely; 4 = Likely; 5 = Very
likely
N2.
Compared to other people your age, how likely are you to get cancer in your lifetime?
(CompareChanceGetCancer)
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N3.

N4.

N5.

N6.

N7.

1. 1 Much less likely;
2. 2 Less likely;
3. 3 About the same;
4. 4 More likely;
5. 5 Much more likely
Select one answer that best represents your opinion about the statement: "I feel like I
could easily get cancer in my lifetime." (EasilyGetCancer)
1. I feel very strongly that this will NOT happen
2. I feel somewhat strongly that this will NOT happen
3. I feel I am just as likely to get cancer as I am to not get cancer
4. I feel somewhat strongly that this WILL happen
5. I feel very strongly that this WILL happen
How much do you agree or disagree with the statement: "I'd rather not know my chance
of getting cancer." (RatherNotKnowChance)
1. Strongly agree
2. Somewhat agree
3. Somewhat disagree
4. Strongly disagree
How much do you agree or disagree with each of the following statements?
1. It seems like everything causes cancer. (EverythingCauseCancer)
2. There‟s not much you can do to lower your chances of getting cancer.
(PreventNotPossible)
3. There are so many different recommendations about preventing cancer, it's hard to
know which ones to follow (TooManyRecommendations)
4. Some cancers are slow growing and need no treatment (CancerSlowGrowing)
5. In adults, cancer is more common than heart disease. (CancerMoreCommon)
6. In women, breast cancer is more common than lung cancer.
(BreastCancerMoreCommon)
As far as you know, who has a greater chance of getting cancer - a person with a 1 in
1,000 chance of getting cancer, or a person with a 1 in 100 chance?
(WhichRatioCancerChance)
2 = 1 in 1,000 is a greater chance of getting cancer
1 = 1 in 100 is a greater chance of getting cancer
Have any of your family members ever had cancer? (FamilyEverHadCancer)
1 = Yes; 2 = No; 4 = Not sure

Sociodemographic Questions
O1.
What is your age? (Age)
O2.
What is your current occupational status? (OccupationStatus) Mark only one.
1. 1 Employed (Employed)
2. 2 Unemployed (Unemployed)
3. 3 Homemaker (Homemaker)
4. 4 Student (Student)
5. 5 Retired (Retired)
6. 6 Disabled (Disabled)
7. 91 Other-Specify (OccupationStatus_OS) (OtherOcc) (MultiOcc)
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O5.

What is your marital status? (MaritalStatus)
1. 1 Married
2. 2 Living as married
3. 3 Divorced
4. 4 Widowed
5. 5 Separated
6. 6 Single, never been married
O6.
What is the highest grade or level of schooling you completed? (Education)
1. Less than 8 years
2. 8 through 11 years
3. 12 years or completed high school
4. Post high school training other than college (vocational or technical)
5. Some college
6. College graduate
7. Postgraduate
O10. Are you of Hispanic, Latino/a, or Spanish origin? One or more categories may be
selected. Mark one or more.
1. No, not of Hispanic, Latino/a, or Spanish origin (NotHis)
2. Yes, Mexican, Mexican American, Chicano/a (Mexican)
3. Yes, Puerto Rican (PuertoRican)
4. Yes, Cuban (Cuban)
5. Yes, another Hispanic, Latino/a, or Spanish origin (OthHisp) (Hisp_Cat)
O11. What is your race? One or more categories may be selected. Mark one or more.
1. White (White)
8. Korean (Korean)
2. Black or African American
9. Vietnamese (Vietnamese)
(Black)
10. Other Asian (OthAsian)
3. American Indian or Alaska
11. Native Hawaiian (Hawaiian)
Native (AmerInd)
12. Guamanian or Chamorro
4. Asian Indian (AsInd)
(Guamanian)
5. Chinese (Chinese)
13. Samoan (Samoan)
6. Filipino (Filipino)
14. Other Pacific Islander
7. Japanese (Japanese)
(OthPacIsl) (Race_Cat2 )
O18. Thinking about members of your family living in this household, what is your combined
annual income, meaning the total pre-tax income from all sources earned in the past year?
(IncomeRanges).
1. $0 to $9,999
2. $10,000 to $14,999
3. $15,000 to $19,999
4. $20,000 to $34,999
5. $35,000 to $49,999
6. $50,000 to $74,999
7. $75,000 to $99,999
8. $100,000 to $199,999
9. $200,000 or more
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